http://pharmadispatch.com/news/what-can-we-expect-in-2013 2013-01-14T20:57:37+11:00 http://pharmadispatch.com/news/pfizer-considers-global-fast-track-for-new-breast-cancer-drug 2013-01-16T19:03:34+11:00 http://pharmadispatch.com/news/another-tga-safety-advisory-for-dodgy-products 2013-01-16T19:15:48+11:00 http://pharmadispatch.com/news/vaccination-turf-war-heats-up 2013-01-16T19:18:42+11:00 http://pharmadispatch.com/news/new-az-global-structure-not-expected-to-impact-locally 2013-01-17T18:46:46+11:00 http://pharmadispatch.com/news/progress-for-novartis-men-b-vaccine 2013-01-17T18:44:51+11:00 http://pharmadispatch.com/news/tga-wants-better-communication 2013-01-18T19:11:21+11:00 http://pharmadispatch.com/news/nps-encourages-pharmacists-to-educate-consumers-about-generics 2013-01-18T19:14:14+11:00 http://pharmadispatch.com/news/support-grows-for-pbs-listing-of-hep-c-medicines 2013-01-18T19:18:41+11:00 http://pharmadispatch.com/news/the-focus-is-innovation-at-abbvie-australia 2013-01-21T18:16:57+11:00 http://pharmadispatch.com/news/pharmaleaders-kirsten-odoherty-managing-director-abbvie-australi 2013-01-21T18:19:13+11:00 http://pharmadispatch.com/news/draconian-laws-the-next-move-against-industry-sales 2013-01-21T18:31:42+11:00 http://pharmadispatch.com/news/risks-and-opportunity-in-an-election-year 2013-01-21T18:27:24+11:00 http://pharmadispatch.com/news/nps-backs-champix-safety 2013-01-21T18:14:30+11:00 http://pharmadispatch.com/news/amgen-targets-asia-pacific-with-singapore-investment 2013-01-21T18:13:19+11:00 http://pharmadispatch.com/news/ama-scrap-pbs-authority-system 2013-01-22T18:37:45+11:00 http://pharmadispatch.com/news/guild-rejects-claims-of-a-culture-of-underpayments 2013-01-22T18:32:53+11:00 http://pharmadispatch.com/news/over-9-million-in-government-funding-for-the-chf 2013-01-22T18:50:45+11:00 http://pharmadispatch.com/news/tga-publishes-evidence-in-response-to-criticism-of-labelling-and 2013-01-23T18:46:39+11:00 http://pharmadispatch.com/news/round-2-apesma-and-the-pharmacy-guild 2013-01-23T19:22:30+11:00 http://pharmadispatch.com/news/aspirin-link-to-macular-degeneration 2013-01-23T18:41:35+11:00 http://pharmadispatch.com/news/hand-written-code-complaint-frustrates-all-involved 2013-01-23T19:21:10+11:00 http://pharmadispatch.com/news/new-general-manager-for-lilly-australia-nz 2013-01-24T19:14:04+11:00 http://pharmadispatch.com/news/consumer-pharmaceutical-prices-fall-again-but-it-is-not-what-it- 2013-01-24T18:18:32+11:00 http://pharmadispatch.com/news/australian-isolation-on-anticoagulants-as-uk-nice-backs-eliquis 2013-01-24T18:21:34+11:00 http://pharmadispatch.com/news/fourth-quarter-reports-jj-novartis-amgen 2013-01-24T19:12:47+11:00 http://pharmadispatch.com/news/i-have-discretion-on-price-disclosure-process-minister-tells-cou 2013-01-25T18:27:05+11:00 http://pharmadispatch.com/news/health-and-beauty-the-key-to-future-growth-for-api 2013-01-25T18:21:13+11:00 http://pharmadispatch.com/news/what-do-the-supermarkets-think-about-pharmacy-growing-their-reta 2013-01-25T18:23:45+11:00 http://pharmadispatch.com/news/anticoagulant-review-a-bargain-for-government 2013-01-29T18:29:02+11:00 http://pharmadispatch.com/news/politics-and-personal-relationships-key-to-cabinet-process 2013-01-29T18:46:18+11:00 http://pharmadispatch.com/news/a-busy-time-of-transition-for-bms 2013-01-29T18:21:41+11:00 http://pharmadispatch.com/news/complementary-medicines-strike-out-in-compliance-audits 2013-01-29T18:24:34+11:00 http://pharmadispatch.com/news/cabinet-and-share-of-voice 2013-01-30T18:56:47+11:00 http://pharmadispatch.com/news/pfizer-weathering-patent-losses-and-building-pipeline 2013-01-30T18:49:32+11:00 http://pharmadispatch.com/news/lilly-beats-expectations-on-the-back-of-new-products-and-cost-co 2013-01-30T18:47:21+11:00 http://pharmadispatch.com/news/api-usual-distribution-operations-despite-flood 2013-01-30T18:45:53+11:00 http://pharmadispatch.com/news/doha-response-on-listing-delays-masks-bigger-story 2013-01-31T18:37:43+11:00 http://pharmadispatch.com/news/election-announcement-with-implications-for-the-pharmaceutical-s 2013-01-31T01:40:15+11:00 http://pharmadispatch.com/news/substitution-battle-heads-to-pbac 2013-01-31T18:36:01+11:00 http://pharmadispatch.com/news/publication-of-pbac-agenda-sparks-potential-patent-dispute 2013-02-01T18:16:34+11:00 http://pharmadispatch.com/news/doctors-and-pharmacists-fight-it-out-over-online-poll 2013-01-31T23:46:16+11:00 http://pharmadispatch.com/news/medicines-australia-welcome-coalition-commitment-on-pbs 2013-02-01T02:33:31+11:00 http://pharmadispatch.com/news/fda-committee-sends-pharmaxis-back-to-the-drawing-board 2013-02-01T18:05:02+11:00 http://pharmadispatch.com/news/ma-budget-submission-social-compact-under-pressure 2013-02-01T20:31:17+11:00 http://pharmadispatch.com/news/merck-delays-osteoporosis-drug 2013-02-04T17:53:12+11:00 http://pharmadispatch.com/news/more-change-on-the-way-at-az 2013-02-04T17:55:36+11:00 http://pharmadispatch.com/news/countdown-20-days-to-meet-mou-cabinet-commitment 2013-02-04T18:00:42+11:00 http://pharmadispatch.com/news/nps-dismisses-guild-call-on-home-medicine-reviews 2013-02-04T17:57:03+11:00 http://pharmadispatch.com/news/ma-calls-for-ministerial-intervention-as-australian-patients-mis 2013-02-04T18:20:10+11:00 http://pharmadispatch.com/news/agreement-its-a-problem-but-solution-could-be-hard-to-find 2013-02-04T18:18:42+11:00 http://pharmadispatch.com/news/organisations-lining-up-against-the-guild-on-hmrs-and-everything 2013-02-05T17:57:22+11:00 http://pharmadispatch.com/news/patient-groups-urge-listing-without-delay 2013-02-05T17:54:17+11:00 http://pharmadispatch.com/news/ausbiotech-joins-ma-fight-against-govt-on-new-presentations 2013-02-05T18:01:03+11:00 http://pharmadispatch.com/news/expert-calls-for-review-of-pbs-co-payment-structure 2013-02-05T17:49:52+11:00 http://pharmadispatch.com/news/estimated-2011-12-pbs-spend-was-wrong-by-358-million 2013-02-05T23:13:32+11:00 http://pharmadispatch.com/news/govt-wants-massive-price-cut-for-medicines-to-treat-alzheimers-d 2013-02-06T18:31:53+11:00 http://pharmadispatch.com/news/industry-frustration-over-gaming-of-mou 2013-02-07T17:59:40+11:00 http://pharmadispatch.com/news/more-industry-critics-join-ma-transparency-group 2013-02-07T17:50:29+11:00 http://pharmadispatch.com/news/record-export-performance-despite-difficult-business-environment 2013-02-07T17:40:46+11:00 http://pharmadispatch.com/news/govt-budgets-another-640-million-saving-on-chemo-drugs 2013-02-08T18:06:51+11:00 http://pharmadispatch.com/news/six-months-to-cabinet-but-not-to-listing 2013-02-08T18:01:31+11:00 http://pharmadispatch.com/news/govt-no-evidence-that-discounting-is-higher-in-first-month 2013-02-08T17:59:47+11:00 http://pharmadispatch.com/news/late-stage-pipeline-and-emerging-markets-the-key-for-gsk 2013-02-11T17:57:39+11:00 http://pharmadispatch.com/news/growth-platforms-deliver-for-sanofi 2013-02-11T17:54:40+11:00 http://pharmadispatch.com/news/have-emerging-markets-emerged 2013-02-11T02:35:51+11:00 http://pharmadispatch.com/news/countdown-closing-in-on-cabinet-consideration 2013-02-11T18:06:01+11:00 http://pharmadispatch.com/news/battle-over-patent-term-extension-gets-public-hearing 2013-02-11T17:59:43+11:00 http://pharmadispatch.com/news/tga-reaffirms-benefits-of-pradaxa 2013-02-11T18:00:59+11:00 http://pharmadispatch.com/news/gmia-scrap-price-disclosure-and-introduce-barriers-to-originator 2013-02-12T18:25:00+11:00 http://pharmadispatch.com/news/no-moratorium-but-hmrs-to-be-reviewed 2013-02-12T18:08:33+11:00 http://pharmadispatch.com/news/new-leader-for-pfizer-australia 2013-02-12T02:58:23+11:00 http://pharmadispatch.com/news/gmia-options-paper-looking-beyond-the-election 2013-02-12T18:29:38+11:00 http://pharmadispatch.com/news/cabinet-d-day-for-hep-c-medicines 2013-02-12T18:13:23+11:00 http://pharmadispatch.com/news/in-conversation-with-andrew-carter-managing-director-commercial- 2013-02-13T18:00:01+11:00 http://pharmadispatch.com/news/amgen-and-ucb-focus-on-post-menopausal-osteoporosis 2013-02-13T17:30:43+11:00 http://pharmadispatch.com/news/another-day-another-review 2013-02-13T18:03:55+11:00 http://pharmadispatch.com/news/immunisation-strategy-3-years-late-and-delayed-again 2013-02-14T17:25:46+11:00 http://pharmadispatch.com/news/record-result-for-csl 2013-02-14T17:23:39+11:00 http://pharmadispatch.com/news/gmia-remove-originators-from-the-pbs-and-save-200-million 2013-02-14T17:46:53+11:00 http://pharmadispatch.com/news/senator-this-is-a-cheap-shot 2013-02-14T17:32:22+11:00 http://pharmadispatch.com/news/senator-richard-di-natale-an-honest-broker 2013-02-15T18:25:51+11:00 http://pharmadispatch.com/news/patients-could-be-waiting-for-new-presentations 2013-02-14T17:44:16+11:00 http://pharmadispatch.com/news/seven-policy-options-of-the-gmia 2013-02-14T19:32:31+11:00 http://pharmadispatch.com/news/ma-hits-back-at-department-over-evergreening-claims 2013-02-15T18:39:54+11:00 http://pharmadispatch.com/news/ma-and-gmia-come-to-blows 2013-02-15T18:12:44+11:00 http://pharmadispatch.com/news/barnes-transparency-principles-finalised 2013-02-18T18:36:29+11:00 http://pharmadispatch.com/news/just-a-type-of-rat-poison-says-mp 2013-02-18T18:37:41+11:00 http://pharmadispatch.com/news/industry-hits-back-at-pbac-chair 2013-02-18T18:21:36+11:00 http://pharmadispatch.com/news/health-funds-favour-homeopathy-and-herbalism-over-prescriptions 2013-02-19T18:04:39+11:00 http://pharmadispatch.com/news/gmia-fights-to-set-the-agenda 2013-02-18T18:39:47+11:00 http://pharmadispatch.com/news/patent-system-in-systemic-failure-according-to-generics-industry 2013-02-18T18:26:38+11:00 http://pharmadispatch.com/news/innovation-statements-makes-clear-that-govt-purchasing-impacts-i 2013-02-18T18:42:42+11:00 http://pharmadispatch.com/news/chf-dodges-transparency-again 2013-02-19T18:03:33+11:00 http://pharmadispatch.com/news/chfs-own-goal-on-transparency 2013-02-19T18:07:47+11:00 http://pharmadispatch.com/news/update-post-pbac-listing-times-under-the-mou 2013-02-20T18:26:12+11:00 http://pharmadispatch.com/news/cabinet-approves-hep-c-medicines-2 2013-02-20T18:24:56+11:00 http://pharmadispatch.com/news/no-listing-date-and-then-a-listing-date 2013-02-20T18:28:44+11:00 http://pharmadispatch.com/news/new-chair-for-ma 2013-02-20T18:29:20+11:00 http://pharmadispatch.com/news/criticism-of-price-increases-off-the-mark 2013-02-21T18:06:57+11:00 http://pharmadispatch.com/news/consumers-want-more-participation-in-research 2013-02-21T18:05:19+11:00 http://pharmadispatch.com/news/fladrich-appointment-could-prove-a-masterstroke 2013-02-21T18:43:29+11:00 http://pharmadispatch.com/news/ausbiotech-back-pc-findings-on-compulsory-licensing 2013-02-22T18:16:33+11:00 http://pharmadispatch.com/news/opportunities-for-industry-as-political-debate-turns-to-health 2013-02-22T18:43:52+11:00 http://pharmadispatch.com/news/ma-invokes-mou-as-review-and-generics-deliver-56-price-cut-to-pf 2013-02-25T17:54:35+11:00 http://pharmadispatch.com/news/post-market-reviews-make-a-mockery-of-the-mou 2013-02-25T17:53:03+11:00 http://pharmadispatch.com/news/generic-industry-comes-out-swinging 2013-02-25T17:50:30+11:00 http://pharmadispatch.com/news/remove-interim-from-the-job-title 2013-02-26T17:43:37+11:00 http://pharmadispatch.com/news/tga-expects-delays-in-key-reforms 2013-02-25T17:48:08+11:00 http://pharmadispatch.com/news/artg-update 2013-02-25T17:43:20+11:00 http://pharmadispatch.com/news/lyrica-hits-endpoint-in-epilepsy-trial 2013-02-25T17:47:02+11:00 http://pharmadispatch.com/news/guild-to-survey-membership-on-issues-for-next-agreement 2013-02-25T17:45:47+11:00 http://pharmadispatch.com/news/debate-heats-up-but-what-now 2013-02-26T18:05:34+11:00 http://pharmadispatch.com/news/pipeline-setback-for-merck-serono 2013-02-26T18:03:09+11:00 http://pharmadispatch.com/news/ausbiotech-cautious-on-anztpa-implementation-paper 2013-02-27T18:15:56+11:00 http://pharmadispatch.com/news/ranbaxy-result-hit-by-recall 2013-02-27T18:16:59+11:00 http://pharmadispatch.com/news/medicines-australia-parliamentary-dinner-chair-mark-fladrich 2013-02-22T00:21:04+11:00 http://pharmadispatch.com/news/chf-meets-gmia-but-remains-non-committal-on-substitution-proposa 2013-02-27T18:18:47+11:00 http://pharmadispatch.com/news/lilly-partnership-delivers-for-acrux 2013-02-28T17:10:02+11:00 http://pharmadispatch.com/news/qld-health-blueprint-talks-up-clinical-trials 2013-03-04T17:57:22+11:00 http://pharmadispatch.com/news/coalition-hits-out-on-mou-but-does-not-commit 2013-02-28T17:11:51+11:00 http://pharmadispatch.com/news/report-highlights-impact-of-pain-on-relationships 2013-03-01T16:52:35+11:00 http://pharmadispatch.com/news/martin-cross-what-happens-when-the-music-stops 2013-03-01T16:55:53+11:00 http://pharmadispatch.com/news/bayers-eylea-makes-a-strong-start 2013-03-04T17:58:33+11:00 http://pharmadispatch.com/news/di-natale-legislation-a-pressure-point 2013-03-04T17:57:03+11:00 http://pharmadispatch.com/news/why-no-coalition-commitment-on-the-mou-is-a-problem 2013-03-04T18:00:07+11:00 http://pharmadispatch.com/news/companies-go-political-over-post-market-reviews 2013-03-04T18:15:08+11:00 http://pharmadispatch.com/news/profit-fall-hits-blackmores 2013-03-04T17:56:06+11:00 http://pharmadispatch.com/news/nps-miss-on-side-effects 2013-03-04T17:55:11+11:00 http://pharmadispatch.com/news/consumers-win-as-private-prescriptions-easily-beat-pbs-on-price 2013-03-05T18:08:06+11:00 http://pharmadispatch.com/news/gsk-rejects-committees-push-for-charitable-foundation 2013-03-05T17:57:54+11:00 http://pharmadispatch.com/news/prana-jumps-as-new-data-boosts-pbt2-alzheimers-treatment 2013-03-05T17:55:42+11:00 http://pharmadispatch.com/news/mesoblasts-boosts-cash-to-support-development 2013-03-06T18:06:13+11:00 http://pharmadispatch.com/news/tough-times-for-az-as-crestor-generics-ready-for-launch 2013-03-06T18:09:21+11:00 http://pharmadispatch.com/news/judge-slams-attack-on-expert-witness 2013-03-06T18:11:35+11:00 http://pharmadispatch.com/news/new-course-in-health-pr 2013-03-07T17:38:51+11:00 http://pharmadispatch.com/news/pharmacy-the-big-winner-and-they-know-it 2013-03-07T17:47:01+11:00 http://pharmadispatch.com/news/gmia-pursue-compensation-and-reform-patent-laws 2013-03-07T17:49:43+11:00 http://pharmadispatch.com/news/govt-has-no-case-for-compensation-on-crestor-but-what-about-refo 2013-03-07T18:08:48+11:00 http://pharmadispatch.com/news/a-new-front-opens-in-ma-gmia-battle 2013-03-08T18:20:23+11:00 http://pharmadispatch.com/news/rare-event-triggers-product-notification-for-gsk-flu-vaccine 2013-03-08T17:50:45+11:00 http://pharmadispatch.com/news/australians-happy-with-their-own-health-and-their-gp 2013-03-08T17:49:35+11:00 http://pharmadispatch.com/news/doha-would-be-enjoying-the-fight 2013-03-08T18:18:43+11:00 http://pharmadispatch.com/news/pbac-sanofi-and-az-battle-generics 2013-03-11T18:09:53+11:00 http://pharmadispatch.com/news/anticoagulants-on-the-agenda-as-election-approaches 2013-03-11T18:13:55+11:00 http://pharmadispatch.com/news/new-pbs-savings-a-real-risk-says-guild 2013-03-11T18:07:40+11:00 http://pharmadispatch.com/news/aussie-apathy-on-health-overweight-and-relaxed-about-it 2013-03-11T18:03:04+11:00 http://pharmadispatch.com/news/the-policy-disconnect-on-diabetes-medicines 2013-03-11T18:15:51+11:00 http://pharmadispatch.com/news/more-aussies-on-vitamins-than-prescription-medicines 2013-03-11T18:01:49+11:00 http://pharmadispatch.com/news/guild-vindicated-with-changes-to-home-medicines-review 2013-03-11T18:05:21+11:00 http://pharmadispatch.com/news/artg-update-alphapharm-lines-up-for-crestor-market 2013-03-11T17:57:42+11:00 http://pharmadispatch.com/news/nps-goes-where-it-should-not 2013-03-12T17:52:53+11:00 http://pharmadispatch.com/news/industry-survey-confirms-clinical-trial-delays 2013-03-12T17:37:48+11:00 http://pharmadispatch.com/news/change-pharmacy-agreement-negotiations-says-psa 2013-03-12T17:35:15+11:00 http://pharmadispatch.com/news/govt-tells-cancer-patients-to-ask-for-freebies 2013-03-12T17:41:37+11:00 http://pharmadispatch.com/news/diabetes-review-submissions-more-funding-for-insulin-pumps 2013-03-13T18:03:57+11:00 http://pharmadispatch.com/news/novartis-alumni-takes-the-reins-at-pharmaxis-business-model-unde 2013-03-13T18:06:26+11:00 http://pharmadispatch.com/news/transparency-group-meets-to-considers-draft-model-today 2013-03-13T18:19:36+11:00 http://pharmadispatch.com/news/gonorrhea-infects-nps-policy-priorities 2013-03-13T18:18:03+11:00 http://pharmadispatch.com/news/ma-warning-on-internet-pharmacy 2013-03-14T17:51:09+11:00 http://pharmadispatch.com/news/internet-pharmacy-is-good-for-consumers-and-should-not-be-demoni 2013-03-14T17:53:14+11:00 http://pharmadispatch.com/news/nps-chair-a-wider-role-and-more-sources-of-income 2013-03-14T18:02:33+11:00 http://pharmadispatch.com/news/new-pbac-appointments-shrouded-in-a-lack-of-transparency 2013-03-15T00:35:06+11:00 http://pharmadispatch.com/news/the-lack-of-transparency-in-pbac-appointments-is-a-problem 2013-03-15T18:06:58+11:00 http://pharmadispatch.com/news/sigma-takes-85-million-hit-from-pbs-reforms 2013-03-15T18:01:51+11:00 http://pharmadispatch.com/news/cipla-opens-regional-office-in-melbourne 2013-03-15T17:59:51+11:00 http://pharmadispatch.com/news/govt-avoids-wholesale-changes-to-pbac-while-opposition-slams-lac 2013-03-18T17:30:31+11:00 http://pharmadispatch.com/news/greens-raise-the-possibility-of-not-proceeding-with-code-legisla 2013-03-18T17:31:39+11:00 http://pharmadispatch.com/news/gsk-1-billion-price-tag-for-new-drugs-a-myth 2013-03-18T17:29:04+11:00 http://pharmadispatch.com/news/researchers-urge-caution-on-hiv-functional-cure-study 2013-03-18T17:22:53+11:00 http://pharmadispatch.com/news/deaths-from-heart-disease-continue-to-fall 2013-03-18T17:26:21+11:00 http://pharmadispatch.com/news/guild-under-attack-again 2013-03-17T23:14:39+11:00 http://pharmadispatch.com/news/progress-on-tpp-as-japan-joins-negotiations-but-ip-remains-an-is 2013-03-18T17:24:38+11:00 http://pharmadispatch.com/news/grattan-institute-over-simplifies-and-cherry-picks-pharmac 2013-03-18T17:34:02+11:00 http://pharmadispatch.com/news/industry-unites-to-reject-grattan-institute-proposal 2013-03-18T17:35:44+11:00 http://pharmadispatch.com/news/stroke-foundation-calls-for-action-as-burden-of-disease-hits-50- 2013-03-19T18:00:03+11:00 http://pharmadispatch.com/news/pricing-debate-reveals-divide-as-govt-sides-with-industry 2013-03-19T18:37:59+11:00 http://pharmadispatch.com/news/mp-pbac-is-politicised-damaged-and-compromised 2013-03-19T18:39:12+11:00 http://pharmadispatch.com/news/mp-speaks-with-authority-on-pbs-issues 2013-03-19T18:35:09+11:00 http://pharmadispatch.com/news/az-focuses-global-rd-effort-as-more-jobs-go 2013-03-20T18:29:49+11:00 http://pharmadispatch.com/news/first-head-to-head-trial-for-ra-biologics-delivers-for-roche 2013-03-20T18:06:54+11:00 http://pharmadispatch.com/news/patient-groups-back-portal-for-patient-support-programs 2013-03-20T18:02:09+11:00 http://pharmadispatch.com/news/a-system-under-pressure-as-another-pbac-member-departs 2013-03-20T18:37:42+11:00 http://pharmadispatch.com/news/blow-for-pharmaxis-as-fda-rejects-bronchitol 2013-03-20T18:26:35+11:00 http://pharmadispatch.com/news/john-young-end-the-policy-diversions 2013-03-21T10:00:20+11:00 http://pharmadispatch.com/news/industry-looking-for-a-post-mou-agenda 2013-03-21T10:02:46+11:00 http://pharmadispatch.com/news/ma-chair-sets-a-new-tone-on-industry-priorities 2013-03-21T10:04:16+11:00 http://pharmadispatch.com/news/minister-too-much-certainty-is-not-a-good-thing 2013-03-21T10:06:21+11:00 http://pharmadispatch.com/news/prima-taps-german-research-funds-to-support-cvac-development 2013-03-22T18:22:37+11:00 http://pharmadispatch.com/news/breaking-news-di-natale-secures-senate-inquiry-for-code-legislat 2013-03-21T22:48:06+11:00 http://pharmadispatch.com/news/senate-inquiry-spells-t-r-o-u-b-l-e-for-industry 2013-03-22T18:33:06+11:00 http://pharmadispatch.com/news/another-2300-jobs-to-go-at-az-as-soriot-announces-new-global-str 2013-03-22T18:24:06+11:00 http://pharmadispatch.com/news/big-news-week-for-ms-therapies 2013-03-25T17:54:04+11:00 http://pharmadispatch.com/news/nz-warns-against-adoption-of-grattan-institute-proposals 2013-03-25T18:10:21+11:00 http://pharmadispatch.com/news/guild-calls-on-govt-to-scrap-monthly-pbs-claims-processing-data 2013-03-24T23:14:37+11:00 http://pharmadispatch.com/news/nz-patients-pharmac-lacks-a-sense-of-equity-and-fairness 2013-03-25T18:06:14+11:00 http://pharmadispatch.com/news/originators-come-out-on-top-in-pbac-substitution-battle-2 2013-03-25T18:15:18+11:00 http://pharmadispatch.com/news/evidence-of-who-really-speaks-for-patients 2013-03-25T18:13:10+11:00 http://pharmadispatch.com/news/bayers-eylea-secures-30-market-share-in-just-third-month 2013-03-26T17:51:12+11:00 http://pharmadispatch.com/news/prime-minister-promotes-co-chair-of-parliamentary-friends-of-med 2013-03-25T23:52:05+11:00 http://pharmadispatch.com/news/march-to-put-melanoma-on-national-agenda 2013-03-26T17:45:28+11:00 http://pharmadispatch.com/news/neumann-excited-about-the-challenge-in-health-as-industry-welcom 2013-03-26T17:53:23+11:00 http://pharmadispatch.com/news/experts-say-debate-on-adhd-medication-particularly-unhelpful 2013-03-26T17:47:46+11:00 http://pharmadispatch.com/news/di-natale-cautions-industry-on-code-bill 2013-03-27T17:58:15+11:00 http://pharmadispatch.com/news/submissions-to-chemo-drug-inquiry-call-for-more-funding 2013-03-28T18:16:57+11:00 http://pharmadispatch.com/news/confusion-over-pbac-decision-on-ru486 2013-03-27T18:19:43+11:00 http://pharmadispatch.com/news/ma-goes-digital-with-code-ipad-app 2013-03-28T17:58:56+11:00 http://pharmadispatch.com/news/the-real-thing-to-raise-hep-c-awareness 2013-03-28T18:04:01+11:00 http://pharmadispatch.com/news/finally-pbac-resolution-for-anticoagulants 2013-04-02T18:12:13+11:00 http://pharmadispatch.com/news/anticoagulants-a-political-opportunity-for-minister 2013-04-02T18:12:07+11:00 http://pharmadispatch.com/news/transparency-group-make-progress-on-payment-disclosure-model 2013-04-02T17:56:35+11:00 http://pharmadispatch.com/news/more-good-news-for-biogens-oral-ms-therapy 2013-04-02T17:51:10+11:00 http://pharmadispatch.com/news/another-day-another-pbac-departure 2013-04-02T18:01:47+11:00 http://pharmadispatch.com/news/gsk-spending-announcement-a-sign-of-things-to-come 2013-04-02T17:54:19+11:00 http://pharmadispatch.com/news/patent-report-a-victory-for-generic-sector-but-where-to-from-her 2013-04-03T17:24:26+11:00 http://pharmadispatch.com/news/tga-medicines-safety-update 2013-04-03T15:32:16+11:00 http://pharmadispatch.com/news/govt-urged-to-stop-fiddling-on-anticoagulants 2013-04-03T17:31:44+11:00 http://pharmadispatch.com/news/new-website-and-app-to-promote-comparison-of-reimbursement-syste 2013-04-05T18:02:21+11:00 http://pharmadispatch.com/news/big-week-for-ma-with-amwg-meeting-and-board-retreat 2013-04-08T17:04:16+10:00 http://pharmadispatch.com/news/lifestyle-factors-fuelling-the-fire-of-liver-disease 2013-04-04T18:38:37+11:00 http://pharmadispatch.com/news/govt-patent-report-delivers-a-stunning-blow-to-innovators 2013-04-03T17:27:16+11:00 http://pharmadispatch.com/news/patent-report-triggers-ferocious-debate-as-gruen-defends-recomme 2013-04-04T18:44:37+11:00 http://pharmadispatch.com/news/a-tough-year-for-pharma-as-rd-and-manufacturing-hang-on 2013-04-04T18:41:19+11:00 http://pharmadispatch.com/news/gruen-we-would-have-gone-even-further 2013-04-05T18:00:21+11:00 http://pharmadispatch.com/news/patent-victory-for-bayer 2013-04-05T17:51:28+11:00 http://pharmadispatch.com/news/patent-report-delivered-with-little-involvement-by-doha 2013-04-08T16:56:43+10:00 http://pharmadispatch.com/news/mckeon-review-go-beyond-ctag-recommendations-to-keep-australia-c 2013-04-08T16:58:52+10:00 http://pharmadispatch.com/news/confused-about-the-govts-position-on-ip-you-wouldnt-be-alone 2013-04-08T17:01:12+10:00 http://pharmadispatch.com/news/critics-ramp-up-industry-attacks-with-plan-for-govt-takeover-of- 2013-04-08T17:09:04+10:00 http://pharmadispatch.com/news/reduced-co-pay-take-for-govt-leads-to-pbac-rejection 2013-04-09T17:04:21+10:00 http://pharmadispatch.com/news/artg-update-2 2013-04-08T16:54:26+10:00 http://pharmadispatch.com/news/industry-calls-for-urgent-action-on-clinical-trials 2013-04-09T16:53:15+10:00 http://pharmadispatch.com/news/qld-to-raise-patent-review-with-federal-govt 2013-04-10T16:59:31+10:00 http://pharmadispatch.com/news/gmia-chairman-patent-reform-an-opportunity-for-savings-in-upcomi 2013-04-09T16:56:03+10:00 http://pharmadispatch.com/news/boost-for-bms-az-diabetes-partnership-as-exenatide-transition-co 2013-04-10T17:06:28+10:00 http://pharmadispatch.com/news/ma-and-gmia-clash-again 2013-04-10T17:08:48+10:00 http://pharmadispatch.com/news/only-the-good-parts-of-the-mou-expire-next-year 2013-04-11T17:06:20+10:00 http://pharmadispatch.com/news/govt-rejects-1-million-loss-claim-on-chemo-drugs 2013-04-11T16:59:36+10:00 http://pharmadispatch.com/news/chf-slams-aat-decision-on-painkillers 2013-04-11T16:49:13+10:00 http://pharmadispatch.com/news/new-clinical-trial-for-bronchitol-as-pharmaxis-acts-to-reduce-co 2013-04-11T16:58:00+10:00 http://pharmadispatch.com/news/ausbiotech-backs-mckeon-and-hits-out-at-pharma-patent-review 2013-04-12T17:23:33+10:00 http://pharmadispatch.com/news/children-at-risk-call-for-sanctions-against-anti-vaccination-gro 2013-04-12T17:16:41+10:00 http://pharmadispatch.com/news/budget-games-on-medical-research 2013-04-12T17:07:26+10:00 http://pharmadispatch.com/news/department-faces-questions-on-reviews-lyrica-and-the-life-saving 2013-04-15T16:20:40+10:00 http://pharmadispatch.com/news/patent-review-unrealistic-on-directing-rd 2013-04-15T16:12:37+10:00 http://pharmadispatch.com/news/duckett-backs-cut-to-drug-patents 2013-04-15T16:16:05+10:00 http://pharmadispatch.com/news/artg-update-sanofis-glp-1-agonist 2013-04-15T16:07:30+10:00 http://pharmadispatch.com/news/cmi-flop-not-educational-or-patient-focussed 2013-04-15T16:28:49+10:00 http://pharmadispatch.com/news/cmi-research-is-more-evidence-of-the-urgent-need-for-change 2013-04-15T16:24:12+10:00 http://pharmadispatch.com/news/amwg-meeting-re-energises-relationship 2013-04-15T16:32:39+10:00 http://pharmadispatch.com/news/gmia-govt-to-bank-3-billion-in-savings-from-recent-patent-cases 2013-04-16T15:59:24+10:00 http://pharmadispatch.com/news/sclavos-to-steps-down-to-avoid-political-distractions 2013-04-16T16:06:04+10:00 http://pharmadispatch.com/news/new-guild-president-facing-a-perfect-storm-of-challenges 2013-04-16T16:04:48+10:00 http://pharmadispatch.com/news/pharmacist-union-farewells-guild-president 2013-04-17T16:45:52+10:00 http://pharmadispatch.com/news/panel-recommends-breast-cancer-medicines-for-healthy-women 2013-04-17T16:49:19+10:00 http://pharmadispatch.com/news/chf-calls-for-reform-of-pharmacy-agreement 2013-04-17T16:44:38+10:00 http://pharmadispatch.com/news/dusc-targets-ms-therapies 2013-04-17T17:03:25+10:00 http://pharmadispatch.com/news/calls-for-pbs-reform-get-louder-as-ceda-joins-debate 2013-04-17T17:06:08+10:00 http://pharmadispatch.com/news/is-the-clock-ticking-down-on-a-new-round-of-reform 2013-04-18T17:20:48+10:00 http://pharmadispatch.com/news/1-in-5-hmrs-done-outside-the-home 2013-04-18T17:20:44+10:00 http://pharmadispatch.com/news/ceda-report-littered-with-factual-errors 2013-04-18T17:20:52+10:00 http://pharmadispatch.com/news/api-grows-pharmacy-footprint-as-pbs-reforms-deliver-96-million-d 2013-04-19T16:53:39+10:00 http://pharmadispatch.com/news/jj-delivers-strong-first-quarter-on-the-back-of-prescription-dru 2013-04-19T16:47:02+10:00 http://pharmadispatch.com/news/new-price-disclosure-regulations-take-effect 2013-04-19T16:55:27+10:00 http://pharmadispatch.com/news/governments-welcome-progress-towards-joint-regulatory-agency 2013-04-19T16:39:43+10:00 http://pharmadispatch.com/news/zippy-is-this-the-future-of-pharmacy 2013-04-22T16:42:43+10:00 http://pharmadispatch.com/news/beattie-plays-down-patent-review 2013-04-22T16:48:41+10:00 http://pharmadispatch.com/news/harvey-backs-ma-transparency-model-to-senate-inquiry 2013-04-22T16:48:18+10:00 http://pharmadispatch.com/news/rd-productivity-since-2003 2013-04-22T16:35:16+10:00 http://pharmadispatch.com/news/australia-welcomes-japan-to-tpp-negotiations 2013-04-22T16:40:36+10:00 http://pharmadispatch.com/news/losses-mount-for-ranbaxy-australia-with-another-8-million-in-201 2013-04-23T16:57:45+10:00 http://pharmadispatch.com/news/rare-diseases-growing-a-voice 2013-04-22T16:39:04+10:00 http://pharmadispatch.com/news/ims-clarifies-confusion-over-dr-letter 2013-04-22T16:37:45+10:00 http://pharmadispatch.com/news/artg-update-3 2013-04-22T16:34:26+10:00 http://pharmadispatch.com/news/australian-patents-shifting-from-europe-to-asia 2013-04-23T16:55:32+10:00 http://pharmadispatch.com/news/reissued-ims-letter-refutes-attacks-on-data-collection-program 2013-04-23T16:50:46+10:00 http://pharmadispatch.com/news/qa-health-debate-confirms-the-challenge-for-industry 2013-04-23T17:04:45+10:00 http://pharmadispatch.com/news/api-outlook-dominated-by-industry-headwinds 2013-04-24T17:08:24+10:00 http://pharmadispatch.com/news/govt-uses-40-price-cut-to-end-six-month-rule-for-alzheimers-medi 2013-04-24T17:11:23+10:00 http://pharmadispatch.com/news/is-anymore-evidence-required-to-confirm-that-reviews-are-all-abo 2013-04-24T17:00:29+10:00 http://pharmadispatch.com/news/amgen-profit-grows-as-prolia-sales-surge 2013-04-24T17:05:32+10:00 http://pharmadispatch.com/news/another-blow-for-pharmaxis-as-bronchitol-misses-trial-endpoint 2013-04-26T17:00:51+10:00 http://pharmadispatch.com/news/pbs-reforms-impacting-cpi 2013-04-26T17:03:18+10:00 http://pharmadispatch.com/news/mixed-results-as-companies-battle-patent-cliff-gsk-bi-nvs-lilly- 2013-04-26T16:59:21+10:00 http://pharmadispatch.com/news/jody-fassina-of-statecraft-dont-forget-the-senate 2013-04-29T16:50:07+10:00 http://pharmadispatch.com/news/dr-mark-tennyson-executive-medical-director-amgen-australia 2013-04-29T16:50:01+10:00 http://pharmadispatch.com/news/beattie-urges-industry-not-to-over-react-to-patent-review 2013-04-29T16:44:38+10:00 http://pharmadispatch.com/news/bayers-eylea-approaching-40-market-share 2013-04-29T16:45:32+10:00 http://pharmadispatch.com/news/pbac-approves-ru486 2013-04-27T02:04:43+10:00 http://pharmadispatch.com/news/families-bewildered-by-myozyme-rejection 2013-04-29T16:50:00+10:00 http://pharmadispatch.com/news/latest-attack-on-industry-all-about-the-timing 2013-04-29T16:38:47+10:00 http://pharmadispatch.com/news/michael-wonder-gives-his-perspective-on-march-pbac-outcomes 2013-04-29T16:50:57+10:00 http://pharmadispatch.com/news/cancer-specialists-unite-on-drug-pricing 2013-04-29T16:42:30+10:00 http://pharmadispatch.com/news/two-code-of-conduct-wins-for-az 2013-04-29T16:49:39+10:00 http://pharmadispatch.com/news/senator-scott-ryan-bias-goes-both-ways 2013-04-29T19:46:59+10:00 http://pharmadispatch.com/news/mgsm-targets-pharma-leaders 2013-04-30T16:52:10+10:00 http://pharmadispatch.com/news/ma-holding-govt-to-mou-despite-budget-woes 2013-04-30T17:28:51+10:00 http://pharmadispatch.com/news/legislation-not-going-away 2013-04-30T17:28:14+10:00 http://pharmadispatch.com/news/facts-get-lost-in-chf-campaign 2013-05-01T14:42:50+10:00 http://pharmadispatch.com/news/pfizer-and-merck-to-collaborate-on-diabetes 2013-04-30T19:57:24+10:00 http://pharmadispatch.com/news/humira-drives-abbvie-growth 2013-05-01T02:31:05+10:00 http://pharmadispatch.com/news/ma-patent-review-biased-full-of-factual-errors 2013-05-01T14:34:29+10:00 http://pharmadispatch.com/news/pfizer-trims-forecast-and-looks-to-pipeline-as-patent-expiries-c 2013-05-01T14:00:47+10:00 http://pharmadispatch.com/news/post-market-reviews-not-unique-to-australia 2013-05-01T21:34:00+10:00 http://pharmadispatch.com/news/us-industry-rebukes-patent-review-for-disregarding-australias-in 2013-05-02T16:47:26+10:00 http://pharmadispatch.com/news/high-demand-forces-biocsl-to-restart-production-of-flu-vaccine 2013-05-01T23:15:03+10:00 http://pharmadispatch.com/news/patent-debate-too-simplistic 2013-05-02T16:43:13+10:00 http://pharmadispatch.com/news/medicines-nz-report-a-stark-reminder-of-pharmac-realities 2013-05-02T16:50:24+10:00 http://pharmadispatch.com/news/australians-back-zytiga-listing-without-delay 2013-05-02T16:55:04+10:00 http://pharmadispatch.com/news/merck-cuts-2013-forecast 2013-05-02T21:19:51+10:00 http://pharmadispatch.com/news/dusc-signals-diabetes-price-cut 2013-05-03T16:49:54+10:00 http://pharmadispatch.com/news/guild-raises-risk-of-pbs-budget-cuts 2013-05-02T23:47:46+10:00 http://pharmadispatch.com/news/concern-over-antipsychotic-use-in-elderly 2013-05-03T14:21:03+10:00 http://pharmadispatch.com/news/gmia-welcomes-patent-review-but-calls-for-more-specifics 2013-05-03T14:19:10+10:00 http://pharmadispatch.com/news/artg-update-eliquis-in-atrial-fibrillation 2013-05-06T14:44:44+10:00 http://pharmadispatch.com/news/first-qtr-results-sanofi-shire-gilead-regeneron 2013-05-06T14:30:59+10:00 http://pharmadispatch.com/news/conscientious-objections-to-immunisation-soar 2013-05-06T15:01:01+10:00 http://pharmadispatch.com/news/august-price-cuts-deliver-govt-another-200-million 2013-05-06T15:38:51+10:00 http://pharmadispatch.com/news/beattie-abandon-patent-review 2013-05-06T15:35:09+10:00 http://pharmadispatch.com/news/another-member-departs-pbac-in-disarray 2013-05-07T17:15:14+10:00 http://pharmadispatch.com/news/pbac-self-destructs-could-history-repeat 2013-05-06T16:04:19+10:00 http://pharmadispatch.com/news/plibersek-buys-time-on-chemotherapy-drugs 2013-05-06T15:32:52+10:00 http://pharmadispatch.com/news/budget-savings-would-not-breach-the-mou 2013-05-06T15:40:59+10:00 http://pharmadispatch.com/news/education-program-leads-to-better-pain-management 2013-05-07T16:48:21+10:00 http://pharmadispatch.com/news/zelboraf-decision-appalling-and-a-turning-point 2013-05-07T17:01:59+10:00 http://pharmadispatch.com/news/an-important-brake-on-pbac-power 2013-05-08T16:48:42+10:00 http://pharmadispatch.com/news/bayer-hit-back-at-today-tonight 2013-05-07T22:12:23+10:00 http://pharmadispatch.com/news/busting-the-myths-of-pbs-sustainability 2013-05-08T17:13:02+10:00 http://pharmadispatch.com/news/lessons-for-australia-as-scotland-looks-to-community-opinion-on- 2013-05-08T16:52:43+10:00 http://pharmadispatch.com/news/diabetes-roundtable-as-pbac-calls-for-submissions 2013-05-09T16:38:13+10:00 http://pharmadispatch.com/news/ma-australians-deserve-better-than-cost-containment 2013-05-08T21:45:26+10:00 http://pharmadispatch.com/news/another-cancer-announcement-but-patients-still-waiting-on-medici 2013-05-09T16:41:27+10:00 http://pharmadispatch.com/news/pbs-budget-heading-south 2013-05-09T16:46:22+10:00 http://pharmadispatch.com/news/sigma-signals-acquisitions-to-offset-impact-of-pbs-cuts 2013-05-09T16:00:10+10:00 http://pharmadispatch.com/news/australian-office-for-vertex 2013-05-10T04:37:19+10:00 http://pharmadispatch.com/news/federal-court-backs-az-in-nexium-patent-case 2013-05-11T02:20:20+10:00 http://pharmadispatch.com/news/savings-are-all-upside-for-government 2013-05-10T15:24:00+10:00 http://pharmadispatch.com/news/chf-and-ma-back-moves-to-enhance-pbac-accountability 2013-05-10T15:17:12+10:00 http://pharmadispatch.com/news/ranbaxy-profit-plummets-90 2013-05-10T15:09:37+10:00 http://pharmadispatch.com/news/a-mother-to-the-pm-you-can-open-doors-i-cant 2013-05-13T17:10:07+10:00 http://pharmadispatch.com/news/a-downward-revision-is-a-cut 2013-05-11T22:21:47+10:00 http://pharmadispatch.com/news/msd-building-an-office-where-people-can-also-have-fun 2013-05-13T16:43:54+10:00 http://pharmadispatch.com/news/merck-and-gsk-drop-prices-for-hpv-vaccine-in-developing-countrie 2013-05-13T16:37:46+10:00 http://pharmadispatch.com/news/senate-report-delivers-just-one-recommendation-on-chemo-drugs 2013-05-13T16:49:10+10:00 http://pharmadispatch.com/news/what-is-going-on-with-the-guild 2013-05-13T16:22:43+10:00 http://pharmadispatch.com/news/dusc-analysis-targets-novartis-gilenya 2013-05-14T17:08:22+10:00 http://pharmadispatch.com/news/artg-update-roches-perjeta 2013-05-13T16:33:31+10:00 http://pharmadispatch.com/news/tga-updating-protos-pi-following-european-review 2013-05-13T16:42:08+10:00 http://pharmadispatch.com/news/the-pbs-budget-numbers-to-look-for-and-where-to-find-them 2013-05-14T17:09:55+10:00 http://pharmadispatch.com/news/guild-opens-a-new-front-in-fight-over-chemo-drugs 2013-05-14T16:53:00+10:00 http://pharmadispatch.com/news/a-twist-for-amgens-vectibix 2013-05-14T16:49:46+10:00 http://pharmadispatch.com/news/artg-update-erivedge-for-basal-cell-carcinoma 2013-05-14T16:42:25+10:00 http://pharmadispatch.com/news/tga-calls-for-submissions-on-picmi 2013-05-14T16:45:22+10:00 http://pharmadispatch.com/news/gsk-pharma-drags-on-australian-result 2013-05-15T01:57:47+10:00 http://pharmadispatch.com/news/slow-start-for-global-biosimilar-market-but-growth-will-come 2013-05-15T16:42:23+10:00 http://pharmadispatch.com/news/another-cut-in-pbs-spending-is-it-opportunity-lost 2013-05-15T16:52:21+10:00 http://pharmadispatch.com/news/australian-pharmacists-and-bayer-in-world-first 2013-05-15T16:44:43+10:00 http://pharmadispatch.com/news/govt-cuts-pbs-spend-by-2-8-billion-price-disclosure-to-deliver-3 2013-05-15T17:02:03+10:00 http://pharmadispatch.com/news/doha-funded-for-legal-action 2013-05-15T16:48:03+10:00 http://pharmadispatch.com/news/budget-confirms-innovation-initiatives 2013-05-15T16:46:47+10:00 http://pharmadispatch.com/news/new-listings-not-keeping-pace-with-savings-as-forecast-heads-sou 2013-05-16T16:53:51+10:00 http://pharmadispatch.com/news/pbs-undergoing-massive-structural-change 2013-05-16T16:56:30+10:00 http://pharmadispatch.com/news/doha-claims-faster-post-pbac-process-under-mou-but-avoids-detail 2013-05-16T16:48:19+10:00 http://pharmadispatch.com/news/paying-for-zytiga-a-matter-of-life-and-death 2013-05-16T16:50:47+10:00 http://pharmadispatch.com/news/5-3bn-budget-hit-to-pbs-general-and-concessional-categories 2013-05-17T17:04:03+10:00 http://pharmadispatch.com/news/budget-cut-should-end-discussion-on-further-savings 2013-05-17T16:58:04+10:00 http://pharmadispatch.com/news/pharmaxis-heads-to-the-us-for-critical-fda-meeting 2013-05-17T16:49:47+10:00 http://pharmadispatch.com/news/medicines-nz-slams-pharmac-budget 2013-05-17T16:47:36+10:00 http://pharmadispatch.com/news/department-companies-game-the-system-on-second-brands 2013-05-20T16:45:16+10:00 http://pharmadispatch.com/news/department-defends-post-market-review-process 2013-05-20T16:47:29+10:00 http://pharmadispatch.com/news/jody-fassina-statecraft-shifting-the-goalposts-on-pbs-sustainabi 2013-05-20T16:55:25+10:00 http://pharmadispatch.com/news/susanne-fiedler-managing-director-msd-australia-and-nz 2013-05-20T16:53:42+10:00 http://pharmadispatch.com/news/new-trial-shows-bmd-benefit-of-forteo-prolia-in-combo 2013-05-20T16:43:08+10:00 http://pharmadispatch.com/news/asco-and-oncology-trials-bms-melanoma-combo-roches-obinutuzumab- 2013-05-20T16:41:31+10:00 http://pharmadispatch.com/news/artg-allergans-lumigan-and-bms-kombiglyze 2013-05-20T16:38:50+10:00 http://pharmadispatch.com/news/report-cracks-pbs-sustainability-as-savings-flood-govt-coffers 2013-05-20T16:57:39+10:00 http://pharmadispatch.com/news/ma-debate-over-financial-sustainability-over 2013-05-20T21:03:37+10:00 http://pharmadispatch.com/news/government-hits-back-over-ma-report 2013-05-20T21:18:03+10:00 http://pharmadispatch.com/news/did-anyone-in-govt-actually-read-the-ma-report 2013-05-21T16:48:21+10:00 http://pharmadispatch.com/news/another-20-million-in-az-manufacturing-but-operating-environment 2013-05-21T16:46:09+10:00 http://pharmadispatch.com/news/industry-and-government-slug-it-out-over-forecasts 2013-05-21T16:49:04+10:00 http://pharmadispatch.com/news/novartis-afinitor-extends-time-without-disease-progression-in-wo 2013-05-21T16:44:00+10:00 http://pharmadispatch.com/news/tpp-unlikely-this-year 2013-05-22T17:03:11+10:00 http://pharmadispatch.com/news/bayers-riociguat-shows-benefits-in-pulmonary-arterial-hypertensi 2013-05-22T03:38:09+10:00 http://pharmadispatch.com/news/guild-2010-reforms-300k-hit-to-pharmacies 2013-05-22T17:06:28+10:00 http://pharmadispatch.com/news/mercks-insomnia-drug-effective-but-safer-at-lower-dose 2013-05-22T04:24:08+10:00 http://pharmadispatch.com/news/actavis-acquires-warner-chilcott-in-us5-billion-deal 2013-05-22T06:41:54+10:00 http://pharmadispatch.com/news/diabetes-review-call-for-submissions-goes-public 2013-05-22T17:04:51+10:00 http://pharmadispatch.com/news/pfizer-discontinues-development-of-cancer-drug 2013-05-22T16:54:44+10:00 http://pharmadispatch.com/news/sanofi-and-regeneron-announce-positive-results-for-dupilumab-in- 2013-05-23T16:45:18+10:00 http://pharmadispatch.com/news/gsk-to-cut-120-australian-jobs-with-closure-of-packaging-busines 2013-05-22T22:47:52+10:00 http://pharmadispatch.com/news/ubs-global-life-sciences-conference-amgen-merck-bms-regeneron 2013-05-23T16:49:39+10:00 http://pharmadispatch.com/news/research-australia-opens-nominations-for-annual-awards 2013-05-23T16:40:54+10:00 http://pharmadispatch.com/news/pharmac-gets-the-jump-on-australia-on-consumer-consultation 2013-05-23T17:01:48+10:00 http://pharmadispatch.com/news/tga-approves-lillys-cialis-for-urinary-tract-symptoms 2013-05-24T13:46:47+10:00 http://pharmadispatch.com/news/maestro-google-for-market-access 2013-05-27T17:16:07+10:00 http://pharmadispatch.com/news/ubs-global-life-sciences-conference-mylan-merck-kgaa 2013-05-24T13:53:44+10:00 http://pharmadispatch.com/news/doha-no-link-between-pbac-deferral-and-diabetes-review 2013-05-24T14:27:49+10:00 http://pharmadispatch.com/news/nps-medicinewise-moves-into-medical-tests 2013-05-24T14:00:53+10:00 http://pharmadispatch.com/news/industry-dismay-over-pbac-diabetes-decision 2013-05-27T17:36:35+10:00 http://pharmadispatch.com/news/industry-deserves-better-than-this 2013-05-27T17:23:11+10:00 http://pharmadispatch.com/news/ma-says-time-to-review-pbs-as-minister-acknowledges-slowing-grow 2013-05-27T17:12:43+10:00 http://pharmadispatch.com/news/medimark-the-future-of-industry-sponsored-medical-education 2013-05-27T16:35:26+10:00 http://pharmadispatch.com/news/decision-on-transparency-model-today 2013-05-27T17:20:36+10:00 http://pharmadispatch.com/news/tpp-more-time-required-on-ip-and-market-access 2013-05-27T16:25:11+10:00 http://pharmadispatch.com/news/industry-and-govt-come-to-blows-over-pbs-reports 2013-05-28T16:59:26+10:00 http://pharmadispatch.com/news/a-pattern-develops-on-reviews 2013-05-28T17:01:24+10:00 http://pharmadispatch.com/news/transparency-model-agreed 2013-05-28T16:47:52+10:00 http://pharmadispatch.com/news/pharmaxis-sets-new-path-but-cuts-30-of-staff 2013-05-29T16:42:19+10:00 http://pharmadispatch.com/news/renewed-political-debate-over-pbs-policy 2013-05-29T16:45:34+10:00 http://pharmadispatch.com/news/nps-medicinewise-open-to-paid-work-with-industry 2013-05-29T16:48:01+10:00 http://pharmadispatch.com/news/az-acquires-crestor-combo-candidate 2013-05-29T16:38:58+10:00 http://pharmadispatch.com/news/anao-audit-blow-to-pharmacy 2013-05-29T16:52:19+10:00 http://pharmadispatch.com/news/pbac-agenda-reveals-independent-review-just-the-third-since-2005 2013-05-30T02:17:44+10:00 http://pharmadispatch.com/news/patients-anticipate-funding-for-vertex-cf-drug 2013-05-30T17:01:52+10:00 http://pharmadispatch.com/news/major-parties-should-not-prioritise-their-own-funding-over-patie 2013-05-30T17:02:32+10:00 http://pharmadispatch.com/news/michael-wonder-of-maestro-database-breaks-down-the-july-pbac-age 2013-05-30T17:04:35+10:00 http://pharmadispatch.com/news/michael-wonder-of-maestro-database-breaks-down-the-july-pbac-age 2013-05-31T16:39:54+10:00 http://pharmadispatch.com/news/all-eyes-on-biogens-tecfidera 2013-05-31T17:07:35+10:00 http://pharmadispatch.com/news/nominations-open-for-shire-brave-awards 2013-05-31T16:36:49+10:00 http://pharmadispatch.com/news/cf-patients-take-it-up-to-pm-on-drug-funding 2013-05-31T16:43:45+10:00 http://pharmadispatch.com/news/consumers-win-as-generic-crestor-hits-the-market 2013-06-03T08:53:54+10:00 http://pharmadispatch.com/news/twg-sets-practical-threshold-for-payment-reporting 2013-06-04T17:02:04+10:00 http://pharmadispatch.com/news/updated-analysis-nz-falls-further-behind-on-access 2013-06-03T08:38:53+10:00 http://pharmadispatch.com/news/doha-correspondence-highlights-review-process-issues 2013-06-03T08:59:57+10:00 http://pharmadispatch.com/news/asco-update-bms-nivolumab-merck-kgaa-erbitux-amgens-t-vec-pfizer 2013-06-03T08:32:19+10:00 http://pharmadispatch.com/news/the-private-market-an-alternative-pbs-only-cheaper 2013-06-03T08:41:25+10:00 http://pharmadispatch.com/news/ian-noble-trust-is-essential-for-reform 2013-06-03T08:50:12+10:00 http://pharmadispatch.com/news/ma-chief-goes-homeless-for-a-cause 2013-06-03T08:19:49+10:00 http://pharmadispatch.com/news/high-dose-safety-concerns-over-nsaids 2013-06-03T08:36:18+10:00 http://pharmadispatch.com/news/nps-cautions-over-use-of-statins-in-elderly 2013-06-04T16:54:59+10:00 http://pharmadispatch.com/news/csiro-denies-misleading-novartis 2013-06-04T16:56:43+10:00 http://pharmadispatch.com/news/psa-seeking-a-wider-role-as-bronger-speaks-out 2013-06-04T16:58:35+10:00 http://pharmadispatch.com/news/asco-update-2-novartis-afinitor-bayers-nexavar 2013-06-04T16:49:45+10:00 http://pharmadispatch.com/news/eu-fines-nine-companies-over-pay-for-delay 2013-06-04T16:53:28+10:00 http://pharmadispatch.com/news/ehealth-gaining-momentum-as-more-australians-sign-up-for-pcehr 2013-06-05T16:55:36+10:00 http://pharmadispatch.com/news/government-will-not-back-di-natale-code-bill 2013-06-05T17:00:17+10:00 http://pharmadispatch.com/news/where-is-the-final-report-of-the-patent-review 2013-06-05T16:58:20+10:00 http://pharmadispatch.com/news/efficacy-of-tnf-inhibitors-a-barrier-for-new-therapies 2013-06-05T16:56:34+10:00 http://pharmadispatch.com/news/asco-update-3-boehringer-ingelheims-nintedanib 2013-06-05T16:52:37+10:00 http://pharmadispatch.com/news/jobs-go-at-ma-as-cost-cuts-drive-new-strategic-focus 2013-06-06T00:08:52+10:00 http://pharmadispatch.com/news/senator-links-evergreening-to-access-issues 2013-06-06T17:05:09+10:00 http://pharmadispatch.com/news/almost-1000-drugs-in-development-for-cancer 2013-06-06T17:03:24+10:00 http://pharmadispatch.com/news/cutbacks-a-risk-but-did-they-have-a-choice 2013-06-06T16:53:21+10:00 http://pharmadispatch.com/news/two-pharma-companies-win-best-employer-accreditation 2013-06-06T17:04:52+10:00 http://pharmadispatch.com/news/mp-industry-has-lost-trust-in-government 2013-06-07T16:52:43+10:00 http://pharmadispatch.com/news/halton-new-chair-of-world-health-assembly 2013-06-07T16:50:44+10:00 http://pharmadispatch.com/news/reviews-a-radical-change-from-existing-process-senator 2013-06-07T17:09:46+10:00 http://pharmadispatch.com/news/di-natale-picks-apart-post-market-reviews 2013-06-07T17:03:05+10:00 http://pharmadispatch.com/news/we-will-not-be-cowed-on-patent-costs-halton 2013-06-07T16:54:48+10:00 http://pharmadispatch.com/news/countdown-to-cabinet 2013-06-11T16:57:06+10:00 http://pharmadispatch.com/news/trials-bayers-eylea 2013-06-11T16:49:40+10:00 http://pharmadispatch.com/news/tactical-win-for-bms-in-abilify-patent-case 2013-06-11T16:51:45+10:00 http://pharmadispatch.com/news/az-makes-another-acquisition 2013-06-11T16:48:04+10:00 http://pharmadispatch.com/news/bmj-pursues-diabetes-drugs 2013-06-11T16:56:41+10:00 http://pharmadispatch.com/news/it-is-just-a-process 2013-06-11T17:01:50+10:00 http://pharmadispatch.com/news/industry-sceptical-over-review-meeting 2013-06-12T16:48:18+10:00 http://pharmadispatch.com/news/govt-moves-on-second-brands 2013-06-11T17:03:11+10:00 http://pharmadispatch.com/news/what-next-for-martin-cross 2013-06-12T16:58:29+10:00 http://pharmadispatch.com/news/govt-announces-3-million-in-grants-for-dementia-research 2013-06-12T16:39:22+10:00 http://pharmadispatch.com/news/calls-for-yet-another-review-of-ip-law 2013-06-13T17:06:12+10:00 http://pharmadispatch.com/news/qbiotics-capital-raise-to-fund-development-of-blushwood-cancer-c 2013-06-13T17:02:45+10:00 http://pharmadispatch.com/news/order-of-australia-for-nps-ceo 2013-06-13T16:50:19+10:00 http://pharmadispatch.com/news/next-step-in-guild-succession-plan 2013-06-13T17:11:08+10:00 http://pharmadispatch.com/news/eular-update-bms-orencia 2013-06-13T16:46:53+10:00 http://pharmadispatch.com/news/psa-delivers-pointed-welcome-to-new-guild-leader 2013-06-14T16:53:15+10:00 http://pharmadispatch.com/news/eular-update-amgen-and-azs-brodalumab-roches-actemra 2013-06-14T16:50:24+10:00 http://pharmadispatch.com/news/four-years-to-align-industry-codes 2013-06-14T16:54:34+10:00 http://pharmadispatch.com/news/dr-lynn-weekes-of-nps-medicinewise-a-more-comfortable-relationsh 2013-06-17T15:49:30+10:00 http://pharmadispatch.com/news/michael-wonder-international-comparison-of-recent-reimbursement- 2013-06-17T15:51:25+10:00 http://pharmadispatch.com/news/ma-to-publish-transparency-model-with-options 2013-06-17T15:54:06+10:00 http://pharmadispatch.com/news/industry-gives-review-meeting-a-pass-mark-barely 2013-06-17T15:56:21+10:00 http://pharmadispatch.com/news/trials-bms-and-abbvies-elotuzumab-amgens-trebananib-novartis-jak 2013-06-17T15:43:33+10:00 http://pharmadispatch.com/news/psa-unity-essential-for-pharmacy-profession 2013-06-17T15:45:15+10:00 http://pharmadispatch.com/news/inflation-rise-for-pbac-fees-unlikely-to-fill-budget-hole 2013-06-17T15:46:50+10:00 http://pharmadispatch.com/news/further-confirmation-of-pradaxa-safety 2013-06-18T16:29:03+10:00 http://pharmadispatch.com/news/senate-committee-rejects-di-natale-bill 2013-06-18T17:12:41+10:00 http://pharmadispatch.com/news/industry-lambasts-asthma-review 2013-06-18T17:12:28+10:00 http://pharmadispatch.com/news/industry-meets-it-friends-in-canberra 2013-06-19T16:19:49+10:00 http://pharmadispatch.com/news/gmia-stop-originators-creaming-profits 2013-06-19T16:16:24+10:00 http://pharmadispatch.com/news/show-of-unity-by-pharmacy-groups 2013-06-19T16:10:21+10:00 http://pharmadispatch.com/news/ma-backs-coalition-rd-commitments 2013-06-19T16:13:24+10:00 http://pharmadispatch.com/news/pharmaxis-analysis-shows-cost-savings-from-bronchitol-use 2013-06-20T16:50:38+10:00 http://pharmadispatch.com/news/az-turnaround-starts-with-new-global-hq 2013-06-20T16:48:18+10:00 http://pharmadispatch.com/news/another-ian-frazer-vaccine-in-development 2013-06-20T16:45:14+10:00 http://pharmadispatch.com/news/when-it-comes-to-diabetes-reviews-arent-the-only-problem 2013-06-20T16:54:34+10:00 http://pharmadispatch.com/news/onglyza-disappoints-in-cv-trial 2013-06-20T16:51:48+10:00 http://pharmadispatch.com/news/mps-farewell-parliament-with-parting-shots-on-pbs 2013-06-21T16:50:44+10:00 http://pharmadispatch.com/news/more-evidence-hpv-vaccine-benefits 2013-06-21T16:49:15+10:00 http://pharmadispatch.com/news/labor-mp-speaks-out-on-pbac 2013-06-21T16:57:15+10:00 http://pharmadispatch.com/news/finally-some-common-sense 2013-06-21T16:54:57+10:00 http://pharmadispatch.com/news/transparency-model-goes-public 2013-06-21T20:32:09+10:00 http://pharmadispatch.com/news/playing-a-political-game-on-transparency 2013-06-24T17:08:32+10:00 http://pharmadispatch.com/news/nuts-and-bolts-of-the-transparency-model 2013-06-24T17:05:28+10:00 http://pharmadispatch.com/news/trials-update-73rd-american-diabetes-association-scientific-sess 2013-06-24T17:04:24+10:00 http://pharmadispatch.com/news/barnes-end-of-the-beginning-as-fight-looms-over-disclosure-thres 2013-06-24T17:12:15+10:00 http://pharmadispatch.com/news/david-gallagher-industry-has-a-responsibility-to-advocate-for-ne 2013-06-24T17:19:53+10:00 http://pharmadispatch.com/news/martin-cross-the-new-ma-chair 2013-06-24T20:28:21+10:00 http://pharmadispatch.com/news/chf-confuse-themselves-on-disclosure-model-and-everyone-else 2013-06-24T17:10:13+10:00 http://pharmadispatch.com/news/media-backs-patients-on-access-delays 2013-06-24T17:14:36+10:00 http://pharmadispatch.com/news/international-expert-slams-unreasonable-drug-rejection 2013-06-25T16:49:15+10:00 http://pharmadispatch.com/news/martin-cross-redux-a-smart-choice-for-ma 2013-06-24T20:28:16+10:00 http://pharmadispatch.com/news/gmia-reminds-industry-of-cross-previous-policy-positions-on-pate 2013-06-25T16:45:52+10:00 http://pharmadispatch.com/news/gmia-and-interesting-reminders 2013-06-25T16:44:31+10:00 http://pharmadispatch.com/news/gsk-commits-another-80k-to-promote-adult-immunisation 2013-06-25T16:42:52+10:00 http://pharmadispatch.com/news/final-call-for-nominations-for-research-australia-awards 2013-06-25T16:41:05+10:00 http://pharmadispatch.com/news/industry-welcomes-bipartisan-political-commitment-on-clinical-tr 2013-06-26T16:49:59+10:00 http://pharmadispatch.com/news/groups-claim-confusion-over-pbs-schedule 2013-06-26T16:41:48+10:00 http://pharmadispatch.com/news/reminder-for-parents-on-meningitis-and-vaccines 2013-06-26T16:32:12+10:00 http://pharmadispatch.com/news/worst-of-the-patent-cliff-over-as-biologics-start-to-dominate 2013-06-26T16:38:33+10:00 http://pharmadispatch.com/news/govt-faces-more-pressure-over-listings 2013-06-26T16:55:50+10:00 http://pharmadispatch.com/news/industry-unhappy-over-change-to-pbs-schedule 2013-06-27T16:50:07+10:00 http://pharmadispatch.com/news/political-call-to-action-on-zelboraf 2013-06-27T16:52:07+10:00 http://pharmadispatch.com/news/more-govt-funds-for-dementia 2013-06-27T16:48:33+10:00 http://pharmadispatch.com/news/what-now-for-health 2013-06-27T17:01:11+10:00 http://pharmadispatch.com/news/no-announcement-but-pbac-has-two-new-members 2013-06-27T17:03:20+10:00 http://pharmadispatch.com/news/amgen-makes-top-50-of-brws-best-place-to-work-list 2013-06-28T16:59:11+10:00 http://pharmadispatch.com/news/plibersek-likely-to-remain-in-health 2013-06-28T17:13:33+10:00 http://pharmadispatch.com/news/roche-and-astrazeneca-enter-rd-alliance 2013-06-28T16:54:39+10:00 http://pharmadispatch.com/news/industry-spent-less-than-1-million-on-ad-boards 2013-06-28T20:26:33+10:00 http://pharmadispatch.com/news/two-the-popular-number-when-it-comes-to-ad-boards 2013-07-01T16:59:46+10:00 http://pharmadispatch.com/news/onyx-rejects-amgens-us10-billion-takeover 2013-07-01T16:56:42+10:00 http://pharmadispatch.com/news/chf-welcomes-consultation-on-chemo-review 2013-07-01T16:58:11+10:00 http://pharmadispatch.com/news/govt-sticks-to-mou-with-latest-listing-announcement 2013-07-01T17:04:37+10:00 http://pharmadispatch.com/news/time-to-come-clean-on-pradaxa-and-the-process 2013-07-01T17:10:21+10:00 http://pharmadispatch.com/news/august-listing-for-one-anticoagulant-but-its-not-pradaxa 2013-07-01T17:10:35+10:00 http://pharmadispatch.com/news/1-billion-in-new-listings 2013-07-01T17:10:44+10:00 http://pharmadispatch.com/news/new-oncology-platform-for-merck-serono 2013-07-01T16:50:29+10:00 http://pharmadispatch.com/news/breaking-rudd-confirms-plibersek-in-health 2013-07-02T17:25:23+10:00 http://pharmadispatch.com/news/gmia-doubles-up-on-leadership 2013-07-02T17:14:48+10:00 http://pharmadispatch.com/news/study-backs-eliquis-safety-over-warfarin 2013-07-02T17:12:49+10:00 http://pharmadispatch.com/news/chf-price-disclosure-savings-modest 2013-07-02T17:19:48+10:00 http://pharmadispatch.com/news/private-market-launch-for-menarinis-priligy 2013-07-02T17:00:38+10:00 http://pharmadispatch.com/news/companies-join-amgen-in-race-for-onyx 2013-07-03T16:58:32+10:00 http://pharmadispatch.com/news/nps-medicinewise-pleads-for-an-end-to-overuse-of-antibiotics 2013-07-03T16:49:47+10:00 http://pharmadispatch.com/news/bruce-annabel-a-new-pharmacy-model-to-emerge 2013-07-08T17:16:17+10:00 http://pharmadispatch.com/news/more-australians-choosing-cheaper-private-market-over-pbs 2013-07-03T17:18:58+10:00 http://pharmadispatch.com/news/us-setback-for-mercks-insomnia-drug 2013-07-04T17:13:34+10:00 http://pharmadispatch.com/news/gmia-releases-4-point-election-action-plan 2013-07-04T17:16:38+10:00 http://pharmadispatch.com/news/governments-target-pharmaceutical-spend-as-austerity-bites 2013-07-04T17:15:08+10:00 http://pharmadispatch.com/news/guild-government-declares-war-on-pharmacy 2013-07-05T17:03:31+10:00 http://pharmadispatch.com/news/is-there-political-upside-in-taking-on-pharmacy 2013-07-05T16:57:30+10:00 http://pharmadispatch.com/news/stem-cell-transplants-deliver-hope-for-hiv-cure 2013-07-05T16:55:17+10:00 http://pharmadispatch.com/news/new-vaccines-cut-needle-burden 2013-07-05T16:55:24+10:00 http://pharmadispatch.com/news/kalydeco-another-test-for-pbac 2013-07-08T16:53:31+10:00 http://pharmadispatch.com/news/pivotal-pbac-meeting-as-industry-asks-the-question 2013-07-08T17:19:28+10:00 http://pharmadispatch.com/news/is-the-us-government-watching-as-pbac-considers-review 2013-07-08T17:19:12+10:00 http://pharmadispatch.com/news/psa-calls-for-action-on-chronic-disease 2013-07-08T16:55:33+10:00 http://pharmadispatch.com/news/artg-update-novartis-jakavi-gsks-trobalt 2013-07-08T16:54:29+10:00 http://pharmadispatch.com/news/bayers-xarelto-gets-headstart-on-competition 2013-07-09T17:09:14+10:00 http://pharmadispatch.com/news/new-bms-resource-helps-families-explain-melanoma 2013-07-09T16:58:43+10:00 http://pharmadispatch.com/news/afinitor-returns-to-pbac-but-suffers-blow-in-uk 2013-07-09T16:55:25+10:00 http://pharmadispatch.com/news/novartis-secukinumab-achieves-superiority-in-head-to-head-trial- 2013-07-09T16:52:37+10:00 http://pharmadispatch.com/news/bms-nivolumab-set-to-dominate-global-nsclc-market 2013-07-10T17:15:44+10:00 http://pharmadispatch.com/news/patients-call-for-action-on-bowel-cancer-screening-program 2013-07-10T17:12:59+10:00 http://pharmadispatch.com/news/pharmacs-fentanyl-price-a-90-discount-to-pbs 2013-07-10T17:27:03+10:00 http://pharmadispatch.com/news/amgen-and-servier-announce-product-collaboration 2013-07-14T22:00:00+10:00 http://pharmadispatch.com/news/tga-approves-kalydeco-on-eve-of-pbac-consideration 2013-07-10T17:42:49+10:00 http://pharmadispatch.com/news/zytiga-joins-xarelto-for-1-august-bms-confident-on-yervoy 2013-07-12T17:18:25+10:00 http://pharmadispatch.com/news/mundipharma-wins-oxycontin-patent-case 2013-07-11T17:12:55+10:00 http://pharmadispatch.com/news/patent-settlements-deliver-significant-savings 2013-07-11T16:51:02+10:00 http://pharmadispatch.com/news/roche-scraps-development-of-diabetes-drug 2013-07-11T16:47:29+10:00 http://pharmadispatch.com/news/chief-scientist-sounds-alarm-on-antibiotics 2013-07-11T16:59:04+10:00 http://pharmadispatch.com/news/when-it-comes-to-antibiotics-chief-scientist-gets-it 2013-07-11T16:57:24+10:00 http://pharmadispatch.com/news/gsk-facing-bribery-claims-in-china 2013-07-12T16:58:15+10:00 http://pharmadispatch.com/news/psa-promotes-online-outreach-to-patients 2013-07-12T17:00:12+10:00 http://pharmadispatch.com/news/gsks-geoff-mcdonald-transparency-goes-both-ways 2013-07-15T16:59:31+10:00 http://pharmadispatch.com/news/gsk-joins-public-attack-on-reviews 2013-07-15T16:52:33+10:00 http://pharmadispatch.com/news/companies-hit-the-pain-threshold 2013-07-15T16:55:17+10:00 http://pharmadispatch.com/news/new-reports-shows-why-pbs-has-its-upside 2013-07-15T16:50:49+10:00 http://pharmadispatch.com/news/artg-biogens-tecfidera 2013-07-15T16:44:10+10:00 http://pharmadispatch.com/news/merck-msd-and-lilly-advance-alzheimers-drugs 2013-07-16T14:51:13+10:00 http://pharmadispatch.com/news/patients-pledge-to-make-diabetes-election-issue 2013-07-16T14:53:13+10:00 http://pharmadispatch.com/news/workload-pushes-pbac-process 2013-07-16T14:53:43+10:00 http://pharmadispatch.com/news/jj-result-beats-forecast-on-higher-than-expected-drug-sales 2013-07-17T17:07:39+10:00 http://pharmadispatch.com/news/tpp-talks-underway-as-reminder-of-another-trade-agreement-resurf 2013-07-17T17:16:45+10:00 http://pharmadispatch.com/news/gsk-responds-to-500-million-bribery-allegations 2013-07-17T17:19:02+10:00 http://pharmadispatch.com/news/education-tax-cap-bad-for-health-says-guild 2013-07-17T17:13:24+10:00 http://pharmadispatch.com/news/potential-roche-bid-for-alexion 2013-07-17T17:10:21+10:00 http://pharmadispatch.com/news/election-creates-uncertainty-for-new-listings 2013-07-18T17:11:34+10:00 http://pharmadispatch.com/news/the-long-wait-over-for-pradaxa 2013-07-18T17:11:42+10:00 http://pharmadispatch.com/news/update-post-pbac-listing-times-under-the-mou-including-pradaxa 2013-07-18T17:11:29+10:00 http://pharmadispatch.com/news/lucentis-falls-but-novartis-raises-outlook-on-lower-than-expecte 2013-07-18T16:57:05+10:00 http://pharmadispatch.com/news/pbac-simplifies-bronchitol-prescribing 2013-07-19T16:49:54+10:00 http://pharmadispatch.com/news/bms-confirms-yervoy-for-1-august 2013-07-19T16:52:55+10:00 http://pharmadispatch.com/news/amgens-xgeva-excels-in-bone-tumour-trial 2013-07-19T16:47:58+10:00 http://pharmadispatch.com/news/lundbeck-progressing-alzheimers-therapy 2013-07-19T16:45:50+10:00 http://pharmadispatch.com/news/actelion-raises-guidance-after-successful-cost-cutting-program 2013-07-22T16:39:47+10:00 http://pharmadispatch.com/news/pfizer-withdraws-from-race-for-onyx 2013-07-22T16:40:51+10:00 http://pharmadispatch.com/news/pradaxa-not-the-first-unlikely-to-be-the-last 2013-07-22T16:48:51+10:00 http://pharmadispatch.com/news/china-bribery-investigation-widens-to-other-companies 2013-07-22T16:43:55+10:00 http://pharmadispatch.com/news/tpp-by-year-end-doable-says-us 2013-07-22T16:38:03+10:00 http://pharmadispatch.com/news/industry-waiting-for-answers 2013-07-22T16:45:59+10:00 http://pharmadispatch.com/news/we-appear-to-have-broken-the-law-admits-gsk 2013-07-23T16:41:51+10:00 http://pharmadispatch.com/news/department-funds-chf-on-chemo-review 2013-07-23T16:40:22+10:00 http://pharmadispatch.com/news/pbac-targeting-lucentis-with-off-label-avastin-use 2013-07-23T16:52:19+10:00 http://pharmadispatch.com/news/doha-proposed-stepped-therapy-in-pbs-talks 2013-07-23T16:59:10+10:00 http://pharmadispatch.com/news/chf-backed-fewer-pbs-concession-cards 2013-07-24T17:08:49+10:00 http://pharmadispatch.com/news/consumer-champion-joins-nps-board 2013-07-24T16:45:12+10:00 http://pharmadispatch.com/news/bizarre-proposal-not-good-for-consumers 2013-07-24T17:05:05+10:00 http://pharmadispatch.com/news/az-drawn-into-china-scandal 2013-07-24T16:49:36+10:00 http://pharmadispatch.com/news/tga-bans-natural-sex-pill-found-to-contain-viagra-like-substance 2013-07-24T17:03:48+10:00 http://pharmadispatch.com/news/ma-gmia-agree-on-at-least-one-thing 2013-07-25T17:15:05+10:00 http://pharmadispatch.com/news/positive-results-for-genentech-leukaemia-drug 2013-07-25T17:14:06+10:00 http://pharmadispatch.com/news/2nd-qtr-results-lilly-gsk 2013-07-25T17:14:33+10:00 http://pharmadispatch.com/news/us-and-european-associations-endorse-trial-transparency-principl 2013-07-25T17:13:32+10:00 http://pharmadispatch.com/news/eylea-approaching-50-market-share-as-pbac-targets-lucentis 2013-07-26T17:14:01+10:00 http://pharmadispatch.com/news/new-data-confirms-halt-in-pbs-growth 2013-07-26T17:15:28+10:00 http://pharmadispatch.com/news/canberra-winner-of-the-real-thing-campaign 2013-07-26T17:05:18+10:00 http://pharmadispatch.com/news/company-results-roche-and-bms 2013-07-26T17:08:43+10:00 http://pharmadispatch.com/news/pharmaceuticals-industry-council-introduces-new-chair 2013-07-29T15:30:46+10:00 http://pharmadispatch.com/news/industry-hoping-for-us-style-fast-track-approval-process 2013-07-29T15:28:18+10:00 http://pharmadispatch.com/news/company-results-gilead-abbvie 2013-07-29T15:07:57+10:00 http://pharmadispatch.com/news/complacent-heart-attack-survivors-a-real-problem-says-baker-idi 2013-07-29T15:24:29+10:00 http://pharmadispatch.com/news/artg-shires-vyvanse-another-nexium 2013-07-29T15:04:51+10:00 http://pharmadispatch.com/news/dramatic-decline-in-general-pbs-scripts 2013-07-29T16:06:26+10:00 http://pharmadispatch.com/news/generic-tops-pbs-benefits-but-biologics-on-the-rise 2013-07-29T15:35:53+10:00 http://pharmadispatch.com/news/is-the-pbs-facing-another-big-cut 2013-07-30T17:33:47+10:00 http://pharmadispatch.com/news/retaining-savings-in-the-pbs-would-benefit-everyone 2013-07-30T17:24:39+10:00 http://pharmadispatch.com/news/company-results-biogen-soars-on-tecfidera-sales 2013-07-30T17:22:02+10:00 http://pharmadispatch.com/news/new-pfizer-structure-could-be-prelude-to-breakup 2013-07-30T17:28:07+10:00 http://pharmadispatch.com/news/a-world-class-system-or-is-it 2013-07-31T17:19:32+10:00 http://pharmadispatch.com/news/aussies-lose-out-on-cancer-medicines 2013-07-31T17:28:03+10:00 http://pharmadispatch.com/news/industry-not-spared-in-cancer-report 2013-07-31T17:17:01+10:00 http://pharmadispatch.com/news/report-highlights-nightmare-process-for-co-dependent-technologie 2013-07-31T17:15:27+10:00 http://pharmadispatch.com/news/gmia-chair-ups-the-ante-in-pre-election-push-for-more-generics 2013-07-31T17:26:18+10:00 http://pharmadispatch.com/news/company-results-pfizer-amgen-merck-co 2013-07-31T17:13:03+10:00 http://pharmadispatch.com/news/pharmacy-tax-cap-to-hit-patient-safety 2013-08-01T17:20:42+10:00 http://pharmadispatch.com/news/government-dead-bats-cancer-report 2013-08-01T17:20:47+10:00 http://pharmadispatch.com/news/government-defends-record-on-cancer-medicines 2013-07-31T22:48:29+10:00 http://pharmadispatch.com/news/industry-gears-up-for-fight-over-biosimilars 2013-08-01T17:20:58+10:00 http://pharmadispatch.com/news/novartis-on-the-attack-through-code-of-conduct 2013-08-01T17:20:53+10:00 http://pharmadispatch.com/news/new-report-highlights-benefits-of-pharma-employee-assistance-pro 2013-08-02T17:09:28+10:00 http://pharmadispatch.com/news/company-results-az-sanofi-bayer 2013-08-02T17:08:04+10:00 http://pharmadispatch.com/news/more-experts-join-chorus-on-antibiotics 2013-08-02T17:08:21+10:00 http://pharmadispatch.com/news/guild-wants-a-share-of-tobacco-excise-increase 2013-08-02T17:09:34+10:00 http://pharmadispatch.com/news/another-2-billion-in-pbs-cuts-to-fund-budget-hole 2013-08-02T23:09:32+10:00 http://pharmadispatch.com/news/government-hits-industry-for-835-million-in-new-price-disclosure 2013-08-03T00:08:03+10:00 http://pharmadispatch.com/news/sector-unites-against-price-disclosure-change 2013-08-05T17:29:52+10:00 http://pharmadispatch.com/news/statement-raises-more-questions-than-it-answers-on-pbs 2013-08-05T17:29:44+10:00 http://pharmadispatch.com/news/pharma-joins-the-ranks-of-the-sideswiped-industries 2013-08-05T17:29:32+10:00 http://pharmadispatch.com/news/doha-announces-another-post-market-review 2013-08-05T17:29:48+10:00 http://pharmadispatch.com/news/pharma-facing-pivotal-election 2013-08-05T17:29:38+10:00 http://pharmadispatch.com/news/government-defers-self-education-tax-cap 2013-08-05T17:29:47+10:00 http://pharmadispatch.com/news/guild-claims-32k-hit-to-pharmacy-from-price-disclosure-change 2013-08-06T17:15:46+10:00 http://pharmadispatch.com/news/greens-back-gmia-proposals 2013-08-06T17:12:20+10:00 http://pharmadispatch.com/news/mja-study-backs-nps-cv-programs 2013-08-06T17:08:14+10:00 http://pharmadispatch.com/news/new-survey-reveals-aussies-ignorant-of-their-own-health 2013-08-06T17:08:21+10:00 http://pharmadispatch.com/news/stakeholders-dont-agree-on-very-much 2013-08-07T17:03:58+10:00 http://pharmadispatch.com/news/sigma-downgraded-but-management-gets-benefit-of-the-doubt 2013-08-07T17:03:44+10:00 http://pharmadispatch.com/news/what-about-a-united-front-and-shared-policy-platform 2013-08-07T17:03:47+10:00 http://pharmadispatch.com/news/medicine-exports-fall-as-industry-warns-on-impact-of-unpredictab 2013-08-07T17:03:38+10:00 http://pharmadispatch.com/news/long-term-use-of-ccbs-may-increase-breast-cancer-risk 2013-08-07T17:03:43+10:00 http://pharmadispatch.com/news/amgen-ups-bid-for-onyx 2013-08-08T17:13:25+10:00 http://pharmadispatch.com/news/merck-serono-delivers-strong-earnings-growth-on-cost-cutting-pro 2013-08-08T17:13:16+10:00 http://pharmadispatch.com/news/price-disclosure-change-full-of-surprises 2013-08-08T17:14:16+10:00 http://pharmadispatch.com/news/global-experts-challenge-nhmrc-on-psa-testing 2013-08-08T17:13:34+10:00 http://pharmadispatch.com/news/stakeholders-short-changed-at-diabetes-review-forum 2013-08-09T17:00:01+10:00 http://pharmadispatch.com/news/guild-bets-everything-in-pursuit-of-pre-election-political-commi 2013-08-09T16:59:42+10:00 http://pharmadispatch.com/news/guild-leads-the-way 2013-08-09T16:59:34+10:00 http://pharmadispatch.com/news/patients-demand-political-intervention-on-life-saving-drugs 2013-08-12T17:30:17+10:00 http://pharmadispatch.com/news/review-forum-becomes-a-conference-call 2013-08-12T17:30:25+10:00 http://pharmadispatch.com/news/guild-getting-closer-to-compensation-as-it-ramps-up-pre-election 2013-08-12T17:30:02+10:00 http://pharmadispatch.com/news/doha-under-pressure-as-election-looms 2013-08-12T17:30:09+10:00 http://pharmadispatch.com/news/meeting-the-challenge-of-dr-google 2013-08-12T17:29:52+10:00 http://pharmadispatch.com/news/treasury-the-big-winner-as-risk-share-revenue-grows 2013-08-13T17:19:33+10:00 http://pharmadispatch.com/news/hepatitis-australia-welcomes-federal-funding 2013-08-13T17:19:23+10:00 http://pharmadispatch.com/news/terms-of-reference-reveal-all-current-life-saving-drugs-will-be- 2013-08-13T17:19:45+10:00 http://pharmadispatch.com/news/pefo-gives-nothing-new-on-pbs 2013-08-14T17:03:39+10:00 http://pharmadispatch.com/news/gsk-immunisation-grants-deadline-extended 2013-08-14T17:03:29+10:00 http://pharmadispatch.com/news/chf-lashes-out-of-pockets-costs-and-pharmacy 2013-08-14T17:03:59+10:00 http://pharmadispatch.com/news/pressure-grows-over-life-saving-drugs-review 2013-08-14T17:04:28+10:00 http://pharmadispatch.com/news/pbac-chair-teams-up-with-industry-critics 2013-08-15T17:31:12+10:00 http://pharmadispatch.com/news/csl-talks-down-australia-despite-strong-profit-growth 2013-08-15T17:31:00+10:00 http://pharmadispatch.com/news/mixed-views-on-life-saving-drugs-conference-call 2013-08-15T17:31:23+10:00 http://pharmadispatch.com/news/first-atorvastatin-cut-likely-to-be-over-50 2013-08-16T17:20:19+10:00 http://pharmadispatch.com/news/cystic-fibrosis-patients-set-for-a-long-wait-after-pbac-defers-k 2013-08-15T17:51:26+10:00 http://pharmadispatch.com/news/pharma-patents-review-going-nowhere 2013-08-16T17:20:26+10:00 http://pharmadispatch.com/news/pharmaxis-pushes-on-with-new-strategy 2013-08-16T17:20:13+10:00 http://pharmadispatch.com/news/more-doha-job-cuts-as-efficiency-dividend-hits 2013-08-19T17:07:52+10:00 http://pharmadispatch.com/news/amgen-hits-hurdle-in-onyx-takeover 2013-08-19T17:07:11+10:00 http://pharmadispatch.com/news/no-backing-down-for-the-guild-as-minister-defends-changes 2013-08-19T17:07:28+10:00 http://pharmadispatch.com/news/another-company-dragged-into-china-corruption-scandal 2013-08-19T17:07:19+10:00 http://pharmadispatch.com/news/patent-review-panel-should-have-been-smarter 2013-08-19T17:07:35+10:00 http://pharmadispatch.com/news/cost-of-cancer-medicines-is-not-the-real-issue 2013-08-19T17:07:45+10:00 http://pharmadispatch.com/news/fixed-dose-combinations-targeted 2013-08-19T17:08:00+10:00 http://pharmadispatch.com/news/dusc-to-publish-utilisation-analyses 2013-08-19T17:08:13+10:00 http://pharmadispatch.com/news/dusc-raises-concerns-over-antipsychotics-again 2013-08-20T17:13:05+10:00 http://pharmadispatch.com/news/ms-therapies-off-the-hook 2013-08-20T17:13:15+10:00 http://pharmadispatch.com/news/guild-disgraceful-campaign-designed-to-mislead 2013-08-20T17:13:23+10:00 http://pharmadispatch.com/news/rudd-to-use-pbs-spend-as-leverage-to-encourage-industry-investme 2013-08-21T17:16:30+10:00 http://pharmadispatch.com/news/1-december-price-disclosure-cuts-revealed-over-1-billion-in-savi 2013-08-21T17:16:49+10:00 http://pharmadispatch.com/news/high-stakes-game-will-end-badly-for-someone 2013-08-21T17:16:21+10:00 http://pharmadispatch.com/news/cystic-fibrosis-patients-turn-to-social-media-for-kalydeco 2013-08-21T17:16:39+10:00 http://pharmadispatch.com/news/chf-guild-fight-a-personal-battle-but-far-from-a-genuine-debate 2013-08-22T16:52:04+10:00 http://pharmadispatch.com/news/health-remains-the-top-voter-concern 2013-08-22T16:52:19+10:00 http://pharmadispatch.com/news/bruce-annabel-pharmacy-needs-to-transition 2013-08-23T17:17:34+10:00 http://pharmadispatch.com/news/claim-and-counter-claim-on-health 2013-08-22T17:08:59+10:00 http://pharmadispatch.com/news/coalition-promises-faster-listings-by-doubling-cabinet-threshold 2013-08-22T23:13:48+10:00 http://pharmadispatch.com/news/d-day-with-publication-of-july-pbac-outcomes 2013-08-23T17:17:45+10:00 http://pharmadispatch.com/news/hepatitis-australia-calls-on-coalition-to-back-labor-on-support 2013-08-23T17:14:55+10:00 http://pharmadispatch.com/news/a-good-political-move-at-no-cost 2013-08-23T17:13:00+10:00 http://pharmadispatch.com/news/review-finds-significant-process-issues-within-pbac-says-fladric 2013-08-26T16:50:31+10:00 http://pharmadispatch.com/news/consumers-flocking-to-chemist-warehouse 2013-08-26T16:49:52+10:00 http://pharmadispatch.com/news/industry-be-careful-what-you-wish-for 2013-08-26T16:50:16+10:00 http://pharmadispatch.com/news/pbacs-rejection-of-independent-review-outcomes-only-shows-the-ne 2013-08-26T16:50:21+10:00 http://pharmadispatch.com/news/ama-joins-opposition-to-guild 2013-08-26T16:49:59+10:00 http://pharmadispatch.com/news/vertex-disappointed-at-pbacs-rejection-of-kalydeco-for-life-savi 2013-08-26T16:50:10+10:00 http://pharmadispatch.com/news/pbac-pre-empts-diabetes-review-outcome-again 2013-08-26T16:50:05+10:00 http://pharmadispatch.com/news/michael-wonder-breaks-down-outcomes-from-julys-pbac-meeting 2013-08-26T16:50:26+10:00 http://pharmadispatch.com/news/pbac-issues-reaching-a-critical-mass 2013-08-27T17:14:31+10:00 http://pharmadispatch.com/news/new-research-highlights-benefits-of-surgery-for-type-2-diabetes 2013-08-27T17:14:04+10:00 http://pharmadispatch.com/news/new-high-profile-board-members-for-return-unwanted-medicines-pro 2013-08-27T17:14:11+10:00 http://pharmadispatch.com/news/amgen-seals-deal-for-onyx 2013-08-27T17:14:20+10:00 http://pharmadispatch.com/news/welcome-the-debate-on-the-pricing-of-cancer-drugs 2013-08-27T17:14:26+10:00 http://pharmadispatch.com/news/diabetes-review-will-fail-if-its-just-about-price-says-ma 2013-08-27T17:14:52+10:00 http://pharmadispatch.com/news/chf-reaches-out-to-pharmacists-but-not-the-guild 2013-08-27T17:14:44+10:00 http://pharmadispatch.com/news/plibersek-and-dutton-clash-over-pbs 2013-08-28T00:49:28+10:00 http://pharmadispatch.com/news/bayer-retains-rights-to-onyx-portfolio 2013-08-28T17:34:13+10:00 http://pharmadispatch.com/news/shire-announce-availability-of-new-adhd-drug 2013-08-28T17:34:08+10:00 http://pharmadispatch.com/news/soriot-makes-another-acquisition-for-az 2013-08-28T17:34:02+10:00 http://pharmadispatch.com/news/someone-should-have-shouted-pradaxa 2013-08-28T17:34:18+10:00 http://pharmadispatch.com/news/coalition-banks-835-million-from-price-disclosure-changes 2013-08-28T21:44:01+10:00 http://pharmadispatch.com/news/diabetes-groups-conclude-review-and-improve-access 2013-08-29T17:26:35+10:00 http://pharmadispatch.com/news/for-young-aussie-men-ignorance-is-bliss-when-it-comes-to-prostat 2013-08-29T17:26:22+10:00 http://pharmadispatch.com/news/biogen-to-launch-tecfidera-pfp 2013-08-29T17:26:29+10:00 http://pharmadispatch.com/news/pbac-chair-to-industry-time-to-rethink-your-business-model 2013-08-29T17:26:49+10:00 http://pharmadispatch.com/news/greens-join-coalition-on-pbs-and-target-post-market-reviews 2013-08-29T17:26:42+10:00 http://pharmadispatch.com/news/european-austerity-hits-pharmaxis 2013-08-30T17:03:49+10:00 http://pharmadispatch.com/news/chf-backs-greens-swipes-the-guild-again 2013-08-30T17:03:31+10:00 http://pharmadispatch.com/news/pbs-how-much-out-and-how-much-in 2013-08-30T17:04:02+10:00 http://pharmadispatch.com/news/pharmacy-in-for-a-long-battle-as-industry-likely-to-lock-in-furt 2013-09-02T17:07:36+10:00 http://pharmadispatch.com/news/its-not-all-warfare-between-the-guild-and-government 2013-09-02T17:07:20+10:00 http://pharmadispatch.com/news/artg-gsks-tafinlar-and-a-new-statin 2013-09-02T17:07:12+10:00 http://pharmadispatch.com/news/for-pradaxa-the-wait-is-finally-over 2013-09-02T17:07:29+10:00 http://pharmadispatch.com/news/pbac-looking-for-another-new-member 2013-09-02T17:07:46+10:00 http://pharmadispatch.com/news/unease-over-transparency-as-ma-launches-code-review 2013-09-02T17:08:41+10:00 http://pharmadispatch.com/news/new-study-reveals-issues-with-warfarin 2013-09-03T17:07:07+10:00 http://pharmadispatch.com/news/who-really-represents-diabetes-patients 2013-09-03T17:07:29+10:00 http://pharmadispatch.com/news/urgent-pbs-supply-without-prescription-for-some-patients 2013-09-03T17:07:01+10:00 http://pharmadispatch.com/news/herbalism-and-homeopathy-over-prescription-medicines 2013-09-03T17:07:18+10:00 http://pharmadispatch.com/news/weight-loss-empire-feels-the-pinch 2013-09-04T17:05:19+10:00 http://pharmadispatch.com/news/coalition-could-face-an-early-test-on-pbs 2013-09-04T17:05:49+10:00 http://pharmadispatch.com/news/pharmacy-leadership-heads-overseas 2013-09-04T17:05:40+10:00 http://pharmadispatch.com/news/a-political-concession-with-real-risk 2013-09-04T17:05:29+10:00 http://pharmadispatch.com/news/diabetes-review-could-take-two-years 2013-09-04T17:05:59+10:00 http://pharmadispatch.com/news/labors-health-policies-cost-zero 2013-09-05T17:24:55+10:00 http://pharmadispatch.com/news/coalition-rebuffs-pharmacy-on-compensation-and-other-things 2013-09-05T17:25:48+10:00 http://pharmadispatch.com/news/close-the-policy-gaps-says-ama 2013-09-05T17:24:34+10:00 http://pharmadispatch.com/news/signs-not-good-for-the-guild 2013-09-05T17:25:25+10:00 http://pharmadispatch.com/news/staffers-comments-nothing-to-do-with-us-says-tga 2013-09-06T17:04:53+10:00 http://pharmadispatch.com/news/labor-gives-guild-nothing 2013-09-06T17:04:19+10:00 http://pharmadispatch.com/news/a-conflict-is-a-conflict 2013-09-06T17:04:39+10:00 http://pharmadispatch.com/news/mou-in-chaos-says-liberal-party 2013-09-06T18:04:28+10:00 http://pharmadispatch.com/news/early-months-critical-for-pharma-sector 2013-09-09T16:39:05+10:00 http://pharmadispatch.com/news/how-a-coalition-government-is-different-to-labor 2013-09-09T16:39:13+10:00 http://pharmadispatch.com/news/most-survive-at-least-to-fight-on-for-another-day 2013-09-09T16:39:25+10:00 http://pharmadispatch.com/news/the-transition-to-government-from-someone-who-knows 2013-09-09T16:39:33+10:00 http://pharmadispatch.com/news/industry-confronts-growing-list-of-issues-on-transparency 2013-09-10T17:04:42+10:00 http://pharmadispatch.com/news/getting-control-of-the-health-agenda-and-the-rules-of-engagement 2013-09-10T17:04:52+10:00 http://pharmadispatch.com/news/gsk-sells-popular-consumer-brands 2013-09-10T17:03:11+10:00 http://pharmadispatch.com/news/abbott-rethink-on-industry-portfolio 2013-09-10T17:04:30+10:00 http://pharmadispatch.com/news/boehringer-ingelheims-wes-cook-time-for-a-fresh-start-on-pbs 2013-09-11T16:57:58+10:00 http://pharmadispatch.com/news/15-nominations-for-ma-board 2013-09-11T16:57:50+10:00 http://pharmadispatch.com/news/department-backs-down-on-diabetes-review-forum 2013-09-11T16:57:41+10:00 http://pharmadispatch.com/news/pfizer-successful-drug-development-requires-early-failure 2013-09-12T17:07:59+10:00 http://pharmadispatch.com/news/guild-softens-language 2013-09-12T17:08:06+10:00 http://pharmadispatch.com/news/change-coming-for-pharmacy-and-they-know-it 2013-09-12T17:07:51+10:00 http://pharmadispatch.com/news/sigma-profit-crunched-by-pbs-reforms 2013-09-13T17:14:03+10:00 http://pharmadispatch.com/news/diabetes-forum-constructive-but-what-does-it-change 2013-09-13T17:14:11+10:00 http://pharmadispatch.com/news/az-and-merck-msd-enter-cancer-drug-pact 2013-09-13T17:13:56+10:00 http://pharmadispatch.com/news/mixed-views-on-mirabella-no-show 2013-09-16T17:19:16+10:00 http://pharmadispatch.com/news/the-new-government-means-change-for-everyone 2013-09-16T17:19:08+10:00 http://pharmadispatch.com/news/new-prescribing-conditions-for-controversial-painkillers 2013-09-16T17:19:26+10:00 http://pharmadispatch.com/news/how-about-a-1500-fine-for-every-unique-visitor 2013-09-16T17:19:34+10:00 http://pharmadispatch.com/news/wes-cook-lessons-from-the-pradaxa-journey 2013-09-16T17:19:42+10:00 http://pharmadispatch.com/news/us-disappointed-at-australian-ip-stance 2013-09-16T17:20:06+10:00 http://pharmadispatch.com/news/dutton-in-health-and-sport-as-macfarlane-returns-to-industry 2013-09-17T01:12:45+10:00 http://pharmadispatch.com/news/a-new-ministry-but-what-now 2013-09-17T17:21:29+10:00 http://pharmadispatch.com/news/pharma-and-health-groups-welcome-new-ministry 2013-09-17T17:21:12+10:00 http://pharmadispatch.com/news/businessman-joins-calls-for-overhaul-of-cancer-drug-red-tape 2013-09-17T17:20:58+10:00 http://pharmadispatch.com/news/value-in-early-engagement-with-regulators-and-payors 2013-09-20T17:24:56+10:00 http://pharmadispatch.com/news/tga-acts-after-fda-bans-more-ranbaxy-imports-again 2013-09-18T16:56:10+10:00 http://pharmadispatch.com/news/tga-approves-new-skin-cancer-drug-but-no-pbs 2013-09-18T16:55:59+10:00 http://pharmadispatch.com/news/sclavos-joins-terry-white-board 2013-09-18T16:55:50+10:00 http://pharmadispatch.com/news/chf-slams-aat-over-painkillers 2013-09-18T16:55:41+10:00 http://pharmadispatch.com/news/pfizer-transparency-model-unworkable-and-commercially-unviable 2013-09-18T16:56:19+10:00 http://pharmadispatch.com/news/pfizer-may-be-the-first-of-many 2013-09-18T16:55:29+10:00 http://pharmadispatch.com/news/ban-samples-maybe-ask-the-government-first 2013-09-19T16:24:22+10:00 http://pharmadispatch.com/news/doha-becomes-doh-with-sport 2013-09-19T16:24:55+10:00 http://pharmadispatch.com/news/merck-serono-launches-patient-access-program-for-erbitux 2013-09-19T16:24:33+10:00 http://pharmadispatch.com/news/company-cfos-join-opposition-to-transparency-model 2013-09-19T16:24:42+10:00 http://pharmadispatch.com/news/pharmaxis-trims-board 2013-09-20T17:24:22+10:00 http://pharmadispatch.com/news/prima-slumps-after-ovarian-cancer-drug-disappoints-in-trial 2013-09-20T17:24:08+10:00 http://pharmadispatch.com/news/private-market-growing-and-growing 2013-09-23T16:00:53+10:00 http://pharmadispatch.com/news/is-the-mou-already-dead 2013-09-23T16:01:27+10:00 http://pharmadispatch.com/news/fate-of-the-mou-does-it-really-matter 2013-09-23T16:01:20+10:00 http://pharmadispatch.com/news/1-december-listings-an-early-test-for-dutton 2013-09-23T16:01:04+10:00 http://pharmadispatch.com/news/merck-seronos-shaju-backer-be-prepared-to-put-our-case 2013-09-24T16:41:35+10:00 http://pharmadispatch.com/news/another-pbs-cut 2013-09-23T16:01:13+10:00 http://pharmadispatch.com/news/pbs-forecasts-way-off 2013-09-24T16:39:39+10:00 http://pharmadispatch.com/news/chf-campaign-promoting-a-cheap-and-nasty-regime 2013-09-24T16:35:03+10:00 http://pharmadispatch.com/news/chf-missing-the-point-on-pbs 2013-09-24T16:30:13+10:00 http://pharmadispatch.com/news/ma-companies-unite-against-transparency-model 2013-09-24T16:40:11+10:00 http://pharmadispatch.com/news/qbiotics-taps-investors-to-fund-cancer-drug-development 2013-09-25T17:00:40+10:00 http://pharmadispatch.com/news/ausbiotech-calls-for-tax-break-for-aussie-innovations 2013-09-25T17:01:58+10:00 http://pharmadispatch.com/news/ip-drags-tpp-negotiations 2013-09-25T17:00:58+10:00 http://pharmadispatch.com/news/tga-safety-advisory-on-noacs 2013-09-25T16:59:12+10:00 http://pharmadispatch.com/news/pbs-continues-decade-long-decline 2013-09-26T14:55:32+10:00 http://pharmadispatch.com/news/quilty-the-future-is-what-you-make-of-it 2013-09-26T14:35:10+10:00 http://pharmadispatch.com/news/michael-wonder-breaks-down-the-november-pbac-agenda 2013-09-26T14:36:01+10:00 http://pharmadispatch.com/news/az-facing-fresh-generic-attack-on-nexium 2013-09-26T14:38:46+10:00 http://pharmadispatch.com/news/novartis-takes-top-primary-care-award 2013-09-26T15:36:13+10:00 http://pharmadispatch.com/news/pfizer-announced-closure-of-sydney-manufacturing 2013-09-26T15:35:06+10:00 http://pharmadispatch.com/news/biogen-employees-help-out-on-volunteer-day 2013-09-27T16:55:43+10:00 http://pharmadispatch.com/news/a-new-senate-a-new-ballgame 2013-09-27T16:57:02+10:00 http://pharmadispatch.com/news/ma-another-closure-to-hit-exports 2013-09-27T16:56:11+10:00 http://pharmadispatch.com/news/new-gmia-code-introduces-the-complying-member 2013-09-27T16:56:23+10:00 http://pharmadispatch.com/news/budget-outcome-reveals-pbs-in-free-fall 2013-09-27T22:41:49+10:00 http://pharmadispatch.com/news/more-pbs-cuts-coming 2013-09-30T16:52:06+10:00 http://pharmadispatch.com/news/does-anyone-really-know-whats-happening-with-the-pbs 2013-09-30T16:50:45+10:00 http://pharmadispatch.com/news/industry-ponders-implications-as-hiv-groups-combine-for-pbac-sub 2013-09-30T16:51:11+10:00 http://pharmadispatch.com/news/barnes-heading-for-singapore 2013-09-30T16:50:17+10:00 http://pharmadispatch.com/news/uncertainty-remains-over-1-december-listings-and-cabinet-thresho 2013-09-30T16:50:31+10:00 http://pharmadispatch.com/news/when-it-comes-to-the-pbs-savings-are-in-the-billions 2013-10-01T16:53:41+10:00 http://pharmadispatch.com/news/finally-they-agree-on-something 2013-10-01T16:53:34+10:00 http://pharmadispatch.com/news/amgen-and-gsk-hopeful-of-1-december-listing-for-prolia-in-men 2013-10-01T16:53:27+10:00 http://pharmadispatch.com/news/novartis-and-bayer-dispute-rolls-into-2014 2013-10-01T16:53:18+10:00 http://pharmadispatch.com/news/jason-smith-of-novartis-emerging-lack-of-flexibility-in-a-system 2013-10-03T17:05:59+10:00 http://pharmadispatch.com/news/pbs-share-of-federal-health-spending-plummets 2013-10-02T16:55:47+10:00 http://pharmadispatch.com/news/dept-confirms-reappointment-of-pbac-member 2013-10-02T16:55:39+10:00 http://pharmadispatch.com/news/guild-sells-share-of-it-group-to-telstra 2013-10-02T16:55:31+10:00 http://pharmadispatch.com/news/ma-stay-away-from-ethics-in-patent-grants 2013-10-02T16:55:13+10:00 http://pharmadispatch.com/news/merck-co-sharpens-rd-focus-announces-job-cuts 2013-10-03T17:05:46+10:00 http://pharmadispatch.com/news/the-next-step-for-celgene 2013-10-03T17:05:35+10:00 http://pharmadispatch.com/news/overdiagnosis-anyone 2013-10-04T17:14:15+10:00 http://pharmadispatch.com/news/the-rebranding-of-disease-mongering-as-overdiagnosis 2013-10-04T17:14:01+10:00 http://pharmadispatch.com/news/strategic-acquisition-for-clinical-genomics 2013-10-04T17:13:38+10:00 http://pharmadispatch.com/news/derision-of-disease-awareness-misplaced 2013-10-04T17:13:47+10:00 http://pharmadispatch.com/news/tga-oks-ranbaxy-products-from-mohali-for-now 2013-10-08T18:15:14+11:00 http://pharmadispatch.com/news/mixed-news-on-trade-agreement 2013-10-08T18:15:04+11:00 http://pharmadispatch.com/news/twg-model-dead-in-the-water 2013-10-08T18:15:37+11:00 http://pharmadispatch.com/news/the-drugs-behind-the-falling-pbs 2013-10-08T18:18:28+11:00 http://pharmadispatch.com/news/chf-transparency-submission-a-sign-of-what-could-be-coming 2013-10-08T18:15:21+11:00 http://pharmadispatch.com/news/csl-settles-lawsuit-avoid-further-costs-and-distractions 2013-10-08T18:14:54+11:00 http://pharmadispatch.com/news/a-change-in-government-from-the-departments-perspective 2013-10-09T18:20:38+11:00 http://pharmadispatch.com/news/shaw-hits-back-at-critics-over-pbs-savings 2013-10-09T18:20:29+11:00 http://pharmadispatch.com/news/head-to-head-trial-boosts-erbitux-in-advance-of-pbac 2013-10-09T18:20:17+11:00 http://pharmadispatch.com/news/takedas-james-jones-welcomes-a-more-assertive-industry 2013-10-10T18:12:28+11:00 http://pharmadispatch.com/news/industry-arguments-against-transparency-lame-says-di-natale 2013-10-10T18:12:18+11:00 http://pharmadispatch.com/news/groups-unite-for-world-sight-day 2013-10-10T18:11:50+11:00 http://pharmadispatch.com/news/pharmac-fans-myopic-says-ma 2013-10-10T18:12:08+11:00 http://pharmadispatch.com/news/tpp-leaders-still-working-on-year-end-target 2013-10-10T18:11:59+11:00 http://pharmadispatch.com/news/martin-palin-when-diseases-are-no-laughing-matter 2013-10-11T18:17:45+11:00 http://pharmadispatch.com/news/tga-decides-against-appealing-aat-decision 2013-10-11T18:17:34+11:00 http://pharmadispatch.com/news/pressure-builds-over-1-december-listings-as-treasury-counts-the- 2013-10-11T18:18:31+11:00 http://pharmadispatch.com/news/focus-on-health-not-price-competition-says-quilty 2013-10-11T18:17:56+11:00 http://pharmadispatch.com/news/top-10-heads-south 2013-10-14T18:04:04+11:00 http://pharmadispatch.com/news/new-budget-rules-and-the-pbs 2013-10-14T18:03:38+11:00 http://pharmadispatch.com/news/is-it-really-the-time-for-a-grand-policy-vision 2013-10-14T18:03:56+11:00 http://pharmadispatch.com/news/energised-medical-profession-could-be-industrys-best-asset-on-tr 2013-10-14T18:03:20+11:00 http://pharmadispatch.com/news/shaw-same-tired-arguments-from-the-same-people 2013-10-14T18:03:28+11:00 http://pharmadispatch.com/news/no-excuse-for-the-use-of-warfarin-in-australia-says-global-exper 2013-10-15T17:58:02+11:00 http://pharmadispatch.com/news/survey-finds-most-australians-are-unaware-of-atrial-fibrillation 2013-10-15T17:57:53+11:00 http://pharmadispatch.com/news/plibersek-appointed-deputy-opposition-leader 2013-10-15T17:57:35+11:00 http://pharmadispatch.com/news/ama-backs-company-submissions-on-transparency 2013-10-15T17:57:43+11:00 http://pharmadispatch.com/news/terry-white-pushes-for-pharmacy-access-to-medicare-rebates 2013-10-15T17:57:23+11:00 http://pharmadispatch.com/news/nps-medicine-use-is-a-balance 2013-10-15T17:57:02+11:00 http://pharmadispatch.com/news/a-fresh-start-for-chf 2013-10-16T17:59:55+11:00 http://pharmadispatch.com/news/changes-in-scotland-show-the-way-for-australia 2013-10-16T17:59:36+11:00 http://pharmadispatch.com/news/experts-welcome-new-breast-cancer-drugs 2013-10-16T17:59:31+11:00 http://pharmadispatch.com/news/cv-drugs-on-the-slide-as-patent-expiries-bite 2013-10-17T18:11:27+11:00 http://pharmadispatch.com/news/race-for-new-cholesterol-market-heating-up 2013-10-17T18:11:14+11:00 http://pharmadispatch.com/news/bms-az-diabetes-partnership-celebrates-new-dpp-4-combo 2013-10-17T18:11:03+11:00 http://pharmadispatch.com/news/genzyme-hits-the-bike-path-for-ms 2013-10-18T16:21:44+11:00 http://pharmadispatch.com/news/pbac-approves-sutent-for-pancreatic-cancer-at-special-meeting 2013-10-18T16:21:53+11:00 http://pharmadispatch.com/news/pfizer-calls-on-government-to-establish-cancer-drug-fund 2013-10-18T16:23:08+11:00 http://pharmadispatch.com/news/cancer-fund-makes-sense-if-it-helps-patients 2013-10-18T16:22:29+11:00 http://pharmadispatch.com/news/pharmaxis-cuts-costs-as-bronchitol-sales-accelerate 2013-10-18T16:22:20+11:00 http://pharmadispatch.com/news/labor-sticks-to-its-what-it-know-best-with-health-and-industry-p 2013-10-21T17:36:55+11:00 http://pharmadispatch.com/news/labor-making-its-own-transition 2013-10-21T17:36:46+11:00 http://pharmadispatch.com/news/formation-of-anztpa-more-complex-than-you-think-says-tga 2013-10-21T17:36:32+11:00 http://pharmadispatch.com/news/ma-backs-tga-on-transparency 2013-10-21T17:36:19+11:00 http://pharmadispatch.com/news/roche-reports-strong-growth-for-first-nine-months-of-2013 2013-10-21T17:36:09+11:00 http://pharmadispatch.com/news/big-change-for-pharma-sector-with-new-leadership-and-new-ministe 2013-10-22T17:53:28+11:00 http://pharmadispatch.com/news/obesity-is-a-chronic-disease-say-experts 2013-10-24T18:05:29+11:00 http://pharmadispatch.com/news/stakeholders-united-in-support-of-dpp-4s-at-diabetes-review-foru 2013-10-22T17:53:44+11:00 http://pharmadispatch.com/news/its-official-tambassis-the-new-guild-president 2013-10-22T17:53:09+11:00 http://pharmadispatch.com/news/pfizer-disappointed-after-missing-ma-board 2013-10-23T18:02:42+11:00 http://pharmadispatch.com/news/calibrate-approach-to-ministers-new-reality 2013-10-23T18:02:30+11:00 http://pharmadispatch.com/news/commission-of-audit-to-examine-everything-says-hockey 2013-10-23T18:02:01+11:00 http://pharmadispatch.com/news/political-debate-turns-to-pbs-already 2013-10-24T18:06:22+11:00 http://pharmadispatch.com/news/amgen-goes-from-strength-to-strength 2013-10-24T18:05:39+11:00 http://pharmadispatch.com/news/in-politics-memories-fade-fast 2013-10-24T18:05:50+11:00 http://pharmadispatch.com/news/statecraft-secures-services-of-tga-official 2013-10-25T18:11:46+11:00 http://pharmadispatch.com/news/dutton-secures-key-cabinet-post 2013-10-25T18:12:20+11:00 http://pharmadispatch.com/news/another-rough-day-for-the-pharma-sector 2013-10-25T18:12:04+11:00 http://pharmadispatch.com/news/amgens-pantzer-wins-industry-award 2013-10-25T18:11:54+11:00 http://pharmadispatch.com/news/bayers-eylea-storms-to-market-lead 2013-10-28T18:03:14+11:00 http://pharmadispatch.com/news/evidence-of-pbs-change-emerged-a-long-time-ago 2013-10-28T18:03:41+11:00 http://pharmadispatch.com/news/pbs-falls-but-average-script-cost-continues-to-rise 2013-10-29T17:39:21+11:00 http://pharmadispatch.com/news/dutton-announces-new-listings 2013-10-28T18:06:32+11:00 http://pharmadispatch.com/news/a-strong-start-for-dutton-on-pbs-but-does-he-realise 2013-10-28T18:05:17+11:00 http://pharmadispatch.com/news/company-results-lilly-gsk-and-celgene 2013-10-28T18:02:08+11:00 http://pharmadispatch.com/news/a-stable-environment-says-dutton 2013-10-29T17:39:35+11:00 http://pharmadispatch.com/news/new-meningococcal-vaccine-fronts-pbac 2013-10-29T17:39:11+11:00 http://pharmadispatch.com/news/pbac-set-to-consider-kalydeco-again-in-march 2013-10-29T17:39:02+11:00 http://pharmadispatch.com/news/pfizers-masum-hossain-on-the-pbs-and-cancer-drugs-trying-to-fix- 2013-10-30T18:00:50+11:00 http://pharmadispatch.com/news/abbvie-raising-awareness-of-psoriasis 2013-10-30T18:00:14+11:00 http://pharmadispatch.com/news/results-humira-boosts-abbvie-as-merck-loses-ground-in-diabetes 2013-10-30T18:00:03+11:00 http://pharmadispatch.com/news/leading-clinician-slams-the-abc-over-statins 2013-10-30T18:00:34+11:00 http://pharmadispatch.com/news/dutton-confirms-new-20-million-cabinet-threshold 2013-10-30T22:40:26+11:00 http://pharmadispatch.com/news/far-from-a-small-change 2013-10-31T17:43:06+11:00 http://pharmadispatch.com/news/results-biogen-soars-on-tecfidera-and-pfizer-beats-expectations- 2013-10-31T17:42:46+11:00 http://pharmadispatch.com/news/companies-reassess-listing-timelines 2013-10-31T17:43:21+11:00 http://pharmadispatch.com/news/nps-backs-statin-use-against-abc 2013-11-01T18:02:41+11:00 http://pharmadispatch.com/news/ama-calls-for-change-in-gmia-code 2013-11-01T18:02:28+11:00 http://pharmadispatch.com/news/time-for-a-reality-check 2013-11-01T18:02:00+11:00 http://pharmadispatch.com/news/easier-bronchitol-prescribing-from-today 2013-11-01T18:01:31+11:00 http://pharmadispatch.com/news/results-az-sanofi-and-bayer 2013-11-01T18:01:21+11:00 http://pharmadispatch.com/news/busy-start-for-new-ma-chair 2013-11-04T17:43:01+11:00 http://pharmadispatch.com/news/independent-review-slams-pbac-over-vimovo 2013-11-04T17:43:04+11:00 http://pharmadispatch.com/news/review-provides-further-evidence-of-process-issues 2013-11-04T17:42:58+11:00 http://pharmadispatch.com/news/pbs-sustainable-says-dutton 2013-11-04T17:42:51+11:00 http://pharmadispatch.com/news/new-job-for-carol-bennett 2013-11-04T17:42:29+11:00 http://pharmadispatch.com/news/uncertainty-continues-for-diabetes-companies 2013-11-04T17:42:41+11:00 http://pharmadispatch.com/news/risk-share-revenue-soars-to-350m 2013-11-05T17:59:06+11:00 http://pharmadispatch.com/news/pbs-looks-very-different-today 2013-11-05T17:58:50+11:00 http://pharmadispatch.com/news/leading-clinician-expects-strong-uptake-of-tecfidera 2013-11-05T17:58:39+11:00 http://pharmadispatch.com/news/chf-dodges-transparency-again-2 2013-11-06T17:50:30+11:00 http://pharmadispatch.com/news/non-pbs-grey-market-the-fastest-growing 2013-11-06T17:50:44+11:00 http://pharmadispatch.com/news/time-for-the-facts-on-heart-disease 2013-11-06T17:50:14+11:00 http://pharmadispatch.com/news/another-billion-dollar-fine-against-a-pharma-company 2013-11-06T17:49:33+11:00 http://pharmadispatch.com/news/government-scraps-education-tax-cap 2013-11-07T18:04:37+11:00 http://pharmadispatch.com/news/new-technique-promises-safer-detection-for-cf-patients 2013-11-07T18:04:18+11:00 http://pharmadispatch.com/news/estimates-herald-changing-of-the-guard 2013-11-08T17:59:29+11:00 http://pharmadispatch.com/news/letters-start-arriving-confirming-1-december-listings 2013-11-07T18:04:59+11:00 http://pharmadispatch.com/news/new-survey-reveals-australian-patients-back-industry-rd 2013-11-08T18:01:30+11:00 http://pharmadispatch.com/news/diabetes-cancer-cholesterol-ms-and-osteoporosis-drugs-confirmed- 2013-11-08T17:59:51+11:00 http://pharmadispatch.com/news/pbs-cuts-near-10-billion 2013-11-11T18:11:56+11:00 http://pharmadispatch.com/news/time-to-make-sure-were-getting-it-right 2013-11-11T18:11:42+11:00 http://pharmadispatch.com/news/uncertainty-over-the-fate-of-life-saving-drugs-review 2013-11-11T18:11:28+11:00 http://pharmadispatch.com/news/industry-engages-commission-of-audit 2013-11-11T18:11:16+11:00 http://pharmadispatch.com/news/new-health-channel-just-highlights-the-need-for-change 2013-11-11T18:11:05+11:00 http://pharmadispatch.com/news/nps-reports-a-big-jump-in-pbs-savings-and-adds-mbs 2013-11-12T17:44:18+11:00 http://pharmadispatch.com/news/health-department-silent-on-chf-grants 2013-11-13T17:47:29+11:00 http://pharmadispatch.com/news/four-months-to-cabinet 2013-11-12T17:44:56+11:00 http://pharmadispatch.com/news/department-publishes-patent-watch-list 2013-11-12T17:44:33+11:00 http://pharmadispatch.com/news/media-watch-slams-catalyst-over-statins 2013-11-12T17:44:47+11:00 http://pharmadispatch.com/news/its-all-about-price-and-regulation-says-who-but-what-about-patie 2013-11-14T15:49:36+11:00 http://pharmadispatch.com/news/new-insulin-device-adds-colour 2013-11-13T17:46:53+11:00 http://pharmadispatch.com/news/novartis-sells-diagnostic-unit 2013-11-13T17:47:17+11:00 http://pharmadispatch.com/news/experts-call-for-a-new-national-action-framework-on-dementia 2013-11-13T17:47:06+11:00 http://pharmadispatch.com/news/msds-australia-set-to-launch-its-own-innovation 2013-11-14T15:48:26+11:00 http://pharmadispatch.com/news/leaders-recognised-in-research-australia-awards 2013-11-14T15:48:07+11:00 http://pharmadispatch.com/news/an-austrian-company-growing-in-cochlears-backyard 2013-11-18T17:35:56+11:00 http://pharmadispatch.com/news/dutton-promises-to-fix-chemotherapy-problems 2013-11-14T15:50:10+11:00 http://pharmadispatch.com/news/statin-scripts-fall 2013-11-15T18:13:12+11:00 http://pharmadispatch.com/news/fairfax-youre-confused-and-youre-confusing-the-rest-of-us 2013-11-15T18:12:57+11:00 http://pharmadispatch.com/news/gsk-award-adult-immunisation-grants 2013-11-15T18:12:18+11:00 http://pharmadispatch.com/news/hepatitis-fuelling-growth-in-liver-disease 2013-11-15T18:12:40+11:00 http://pharmadispatch.com/news/australian-link-to-industry-attack-on-uks-nice 2013-11-18T17:36:09+11:00 http://pharmadispatch.com/news/lilly-invests-in-insulin-manufacturing-as-global-epidemic-grows 2013-11-18T17:35:47+11:00 http://pharmadispatch.com/news/dutton-welcomes-ex-mp-as-head-of-diabetes-australia 2013-11-18T17:36:22+11:00 http://pharmadispatch.com/news/pbac-insider-speaks-out 2013-11-18T17:36:43+11:00 http://pharmadispatch.com/news/review-an-opportunity-for-all-including-the-pbac 2013-11-18T17:36:33+11:00 http://pharmadispatch.com/news/pbac-locks-in-sglt2-companies 2013-11-19T17:55:47+11:00 http://pharmadispatch.com/news/nps-and-ama-unite-on-antibiotics 2013-11-19T17:55:28+11:00 http://pharmadispatch.com/news/bard-wins-prestigious-medical-device-award 2013-11-19T17:55:20+11:00 http://pharmadispatch.com/news/ma-meets-dutton 2013-11-19T17:56:00+11:00 http://pharmadispatch.com/news/lundbeck-victorious-in-lexapro-case-while-bayer-scores-tactical- 2013-11-19T17:55:37+11:00 http://pharmadispatch.com/news/msd-drug-boosts-melanoma-survival 2013-11-20T09:53:22+11:00 http://pharmadispatch.com/news/genzymes-aubagio-set-for-1-december 2013-11-20T09:52:54+11:00 http://pharmadispatch.com/news/new-data-backs-pradaxa 2013-11-20T09:52:18+11:00 http://pharmadispatch.com/news/guild-victory-on-chemo-funding-fix 2013-11-20T09:53:53+11:00 http://pharmadispatch.com/news/global-generics-company-exits-australia 2013-11-21T09:42:18+11:00 http://pharmadispatch.com/news/deliver-on-pro-business-rhetoric-ausbiotech-tells-government 2013-11-20T09:54:17+11:00 http://pharmadispatch.com/news/commission-of-audit-brings-in-health-department 2013-11-21T09:41:52+11:00 http://pharmadispatch.com/news/a-quiet-estimates-for-the-pbs 2013-11-21T09:42:02+11:00 http://pharmadispatch.com/news/australian-patients-worry-about-access-delays 2013-11-22T08:49:50+11:00 http://pharmadispatch.com/news/statins-scripts-carry-on-falling 2013-11-22T08:49:36+11:00 http://pharmadispatch.com/news/guild-sharpens-its-tone-on-price-disclosure 2013-11-21T09:41:37+11:00 http://pharmadispatch.com/news/amgen-reports-positive-data-from-new-cholesterol-busting-biologi 2013-11-22T08:49:24+11:00 http://pharmadispatch.com/news/dutton-regrets-price-disclosure-changes 2013-11-22T08:49:40+11:00 http://pharmadispatch.com/news/aussies-love-their-medicine-but-worry-about-access-delays 2013-11-25T10:14:18+11:00 http://pharmadispatch.com/news/patients-use-the-internet-but-dont-trust-it 2013-11-25T10:13:34+11:00 http://pharmadispatch.com/news/patients-facing-a-terrible-situation-without-changes-says-ma-cha 2013-11-25T10:13:43+11:00 http://pharmadispatch.com/news/shaw-slams-productivity-commission 2013-11-25T10:13:22+11:00 http://pharmadispatch.com/news/dutton-sets-a-new-tone-but-sector-cant-break-the-focus-on-cost 2013-11-25T10:14:05+11:00 http://pharmadispatch.com/news/when-it-comes-to-cancer-patients-and-consumers-are-not-the-same- 2013-11-26T09:47:28+11:00 http://pharmadispatch.com/news/grattan-at-it-again-this-time-gst-on-pbs-co-pays 2013-11-26T09:47:48+11:00 http://pharmadispatch.com/news/grattan-institute-seems-very-confused-on-pbs 2013-11-26T09:47:11+11:00 http://pharmadispatch.com/news/ip-sparks-tpp-debate 2013-11-27T09:31:22+11:00 http://pharmadispatch.com/news/new-symbicort-puffer-set-for-pbs 2013-11-27T09:30:52+11:00 http://pharmadispatch.com/news/sort-biosimilars-gmia-tells-commission-of-audit 2013-11-27T09:31:10+11:00 http://pharmadispatch.com/news/prescribers-and-patients-embrace-noacs 2013-11-27T09:32:05+11:00 http://pharmadispatch.com/news/chf-needs-to-be-clear-and-consistent 2013-11-27T09:31:47+11:00 http://pharmadispatch.com/news/pbs-in-the-frame-a-softening-up-process-begins 2013-11-28T09:57:45+11:00 http://pharmadispatch.com/news/information-session-on-price-disclosure-changes 2013-11-28T09:57:27+11:00 http://pharmadispatch.com/news/warfarin-slumps-as-patients-flock-to-noacs 2013-11-28T09:57:37+11:00 http://pharmadispatch.com/news/more-change-in-the-generic-sector 2013-11-28T09:57:09+11:00 http://pharmadispatch.com/news/new-resource-for-lung-cancer-diagnosis 2013-11-29T09:48:12+11:00 http://pharmadispatch.com/news/guild-gets-specific-on-health-services 2013-11-29T09:48:39+11:00 http://pharmadispatch.com/news/more-gp-training-required-on-depression 2013-11-29T09:48:24+11:00 http://pharmadispatch.com/news/ms-patients-waiting-for-sunday 2013-11-29T09:48:49+11:00 http://pharmadispatch.com/news/historic-days-looms-for-pbs 2013-11-29T09:49:34+11:00 http://pharmadispatch.com/news/11784 2013-12-02T09:50:05+11:00 http://pharmadispatch.com/news/we-need-a-national-plan-says-rare-voices 2013-12-02T09:45:56+11:00 http://pharmadispatch.com/news/82-million-for-chemo-drugs 2013-12-02T09:46:07+11:00 http://pharmadispatch.com/news/australia-moves-up-the-obesity-ladder 2013-12-02T09:45:44+11:00 http://pharmadispatch.com/news/focus-on-the-facts-ma-tells-commission-of-audit 2013-12-02T09:46:21+11:00 http://pharmadispatch.com/news/grattan-institute-confused-again 2013-12-02T09:46:35+11:00 http://pharmadispatch.com/news/dusc-targets-cancer-therapies 2013-12-03T10:06:24+11:00 http://pharmadispatch.com/news/new-option-for-melanoma-patients 2013-12-03T10:05:56+11:00 http://pharmadispatch.com/news/moylan-to-co-chair-development-of-new-diabetes-strategy 2013-12-03T10:06:08+11:00 http://pharmadispatch.com/news/report-triggers-new-round-of-debate 2013-12-03T10:06:33+11:00 http://pharmadispatch.com/news/dutton-announces-more-new-listings 2013-12-04T10:16:54+11:00 http://pharmadispatch.com/news/bi-and-lilly-unite-with-idf-on-new-diabetes-survey 2013-12-04T10:15:08+11:00 http://pharmadispatch.com/news/norgine-welcomes-new-listing 2013-12-04T10:14:58+11:00 http://pharmadispatch.com/news/government-commits-another-200-million-to-global-fund 2013-12-04T10:14:46+11:00 http://pharmadispatch.com/news/light-at-the-end-of-the-tunnel-for-kalydeco 2013-12-05T11:03:02+11:00 http://pharmadispatch.com/news/telstra-makes-another-move-into-health 2013-12-05T11:01:07+11:00 http://pharmadispatch.com/news/high-court-finds-methods-of-medical-treatment-are-patentable 2013-12-05T11:04:23+11:00 http://pharmadispatch.com/news/the-2-billion-cost-of-blindness-and-eye-disease 2013-12-05T11:02:25+11:00 http://pharmadispatch.com/news/csl-licenses-cancer-drug-to-janssen 2013-12-06T13:09:39+11:00 http://pharmadispatch.com/news/familiar-names-dominate-new-committees 2013-12-06T13:09:12+11:00 http://pharmadispatch.com/news/40-price-cut-or-youll-be-delisted-dpp-4-companies-told 2013-12-06T13:10:05+11:00 http://pharmadispatch.com/news/extend-ip-for-biologics-us-business-tells-australia 2013-12-09T12:55:56+11:00 http://pharmadispatch.com/news/pbs-facing-the-squeeze-in-2014 2013-12-09T12:55:36+11:00 http://pharmadispatch.com/news/spend-savings-on-pbs-labor-tells-govt 2013-12-09T12:55:24+11:00 http://pharmadispatch.com/news/pbac-wants-action-on-antipsychotics 2013-12-09T12:55:11+11:00 http://pharmadispatch.com/news/one-step-closer-for-pharmacy-on-vaccination 2013-12-09T12:54:58+11:00 http://pharmadispatch.com/news/get-real-on-cancer-drug-debate 2013-12-10T13:07:25+11:00 http://pharmadispatch.com/news/australia-complacent-on-cv-disease 2013-12-10T13:04:10+11:00 http://pharmadispatch.com/news/international-comparisons-suddenly-the-fashion-on-pbs 2013-12-10T13:07:57+11:00 http://pharmadispatch.com/news/more-tppa-leaks-reveal-tense-discussions-on-ip-and-medicines 2013-12-10T13:08:25+11:00 http://pharmadispatch.com/news/crestor-surprises-with-market-share 2013-12-11T13:08:44+11:00 http://pharmadispatch.com/news/mylan-completes-agila-acquisition 2013-12-11T13:07:30+11:00 http://pharmadispatch.com/news/62m-under-co-pay-scripts-as-pbs-plummets 2013-12-11T13:15:22+11:00 http://pharmadispatch.com/news/chf-hits-the-jackpot-on-chemo-review 2013-12-11T13:12:47+11:00 http://pharmadispatch.com/news/growth-will-return-probably-sooner-rather-than-later 2013-12-12T12:43:17+11:00 http://pharmadispatch.com/news/pbs-winds-back-the-clock 2013-12-12T12:43:28+11:00 http://pharmadispatch.com/news/pharmaxis-welcomes-another-bronchitol-approval 2013-12-12T12:42:55+11:00 http://pharmadispatch.com/news/tpp-misses-2013-deadline 2013-12-12T12:43:04+11:00 http://pharmadispatch.com/news/pbs-drives-health-spending-down 2013-12-13T12:54:23+11:00 http://pharmadispatch.com/news/abbvie-oral-hep-c-regimen-cures-96-in-late-stage-trial 2013-12-13T12:54:06+11:00 http://pharmadispatch.com/news/tpp-held-up-by-us-australia-disputes 2013-12-13T12:53:34+11:00 http://pharmadispatch.com/news/are-we-really-going-to-do-this-again 2013-12-16T20:47:17+11:00 http://pharmadispatch.com/news/dept-making-it-up-as-they-go-on-diabetes-says-industry 2013-12-16T20:47:26+11:00 http://pharmadispatch.com/news/big-shift-in-top-ten-still-to-come 2013-12-16T20:47:00+11:00 http://pharmadispatch.com/news/patients-and-doctors-differ-on-e-health-records 2013-12-16T20:46:48+11:00 http://pharmadispatch.com/news/govt-scraps-quarterly-credits-for-rd-tax-inventive 2013-12-16T20:47:09+11:00 http://pharmadispatch.com/news/what-to-expect-from-myefo 2013-12-17T20:02:11+11:00 http://pharmadispatch.com/news/did-they-read-the-same-report 2013-12-17T20:01:45+11:00 http://pharmadispatch.com/news/cancer-medicines-less-than-0-5-of-total-health-spending 2013-12-17T20:01:57+11:00 http://pharmadispatch.com/news/kalydeco-listing-sooner-rather-than-later 2013-12-19T21:19:43+11:00 http://pharmadispatch.com/news/deadline-passes-for-dpp-4-price-cut 2013-12-17T20:02:47+11:00 http://pharmadispatch.com/news/121-drugs-face-1-april-price-disclosure-cuts 2013-12-17T20:02:29+11:00 http://pharmadispatch.com/news/another-2-7-billion-gone-from-the-pbs 2013-12-18T03:15:31+11:00 http://pharmadispatch.com/news/myefo-confirms-pbs-driving-down-health-costs 2013-12-18T20:07:23+11:00 http://pharmadispatch.com/news/hockey-leaves-the-door-ajar-on-pbs 2013-12-18T20:06:51+11:00 http://pharmadispatch.com/news/dutton-announces-more-new-listings-2 2013-12-18T20:06:23+11:00 http://pharmadispatch.com/news/gsk-cuts-doctor-payments 2013-12-18T20:08:00+11:00 http://pharmadispatch.com/news/race-for-new-cholesterol-drugs-heats-up 2013-12-19T21:19:30+11:00 http://pharmadispatch.com/news/gsk-changes-may-catch-amgen 2013-12-19T21:19:13+11:00 http://pharmadispatch.com/news/roche-welcomes-new-tarceva-listing-from-1-january 2013-12-19T21:19:04+11:00 http://pharmadispatch.com/news/1-april-cuts-add-another-1-5-billion-to-savings 2013-12-20T20:42:44+11:00 http://pharmadispatch.com/news/az-buys-bms-out-of-diabetes-partnership 2013-12-20T20:41:48+11:00 http://pharmadispatch.com/news/pbac-approves-wider-access-to-hiv-drugs 2013-12-20T20:42:10+11:00 http://pharmadispatch.com/news/2013-was-tough-but-2014-will-be-tougher 2013-12-20T20:42:21+11:00 http://pharmadispatch.com/news/michael-wonder-breaks-down-the-november-pbac-outcomes 2013-12-23T11:37:31+11:00